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ABSTRACT 
Animal studies to demonstrate efficacy of medical countermeasures against respiratory 
disease or biodefense threats require exposure of animals to aerosolized viruses and bacteria. 
Prior studies have shown that the choice of culture media and relative humidity in the aerosol 
chamber can impact the dose of infectious agent delivered to animals. Most infectious aerosol 
studies have involved the use of Collison jet nebulizers, which create a small, relatively 
monodisperse aerosol that targets the deep lung. Collison nebulizers require a relatively large 
volume of infectious agent, and the jets that create the aerosol may damage the agent being 
aerosolized. Damage resulting from the nebulizer can impact agent infectivity and virulence as 
well as study reproducibility. We compared the Blaustein Atomizing Module (BLAM) and the 
Aeroneb, a vibrating-mesh nebulizer, to the existing ‘gold standard’ Collison nebulizer for 
generation of small particle aerosols containing either a bacterium, F. tularensis, or a virus, 
influenza or Rift Valley Fever Virus (RVFV) in different exposure chambers. Aerosol 
performance was assessed by comparing the spray factor (the ratio between the aerosol 
concentration of an agent and the concentration of the agent in the nebulizer), the reduction in 
pathogen viability, and the aerosol efficiency (the ratio of the actual aerosol concentration to the 
theoretical aerosol concentration. In the Nose-only Tower (NOT), the Collison had superior 
aerosol performance compared to the BLAM and the Aeroneb, while the Aeroneb had superior 
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aerosol performance compared to the Collison in the whole-body and head-only chambers.  
Regression analysis revealed increased humidity was associated with improved aerosol 
performance of F. tularensis, but no environmental factors were associated with improved 
aerosol performance of influenza or RVFV.  This data demonstrates that there is no ‘one size fits 
all’ choice of aerosol generator, and that further characterization of aerosol generators and 
factors that affect aerosol performance is needed to improve selection of aerosol equipment.  The 
public health significance of this research is its contribution to the characterization of available 
aerosol generators to optimize aerosol experiments for a more robust experimental design for 
developing animal models of respiratory infections and developing therapeutics and vaccines 
against potential biological weapons. 
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1.0  INTRODUCTION 
1.1 RESPIRATORY TRANSMISSION OF DISEASE 
Respiratory transmission is the spread of an infection by aerosols or droplets to a susceptible 
individual within close proximity of the infected individual [1, 2].  As global population and 
international travel increases, putting more people in smaller areas, respiratory transmission 
poses a huge obstacle for the prevention of the spread of infectious diseases [3].  There has been 
much debate regarding disease transmission through aerosols [1].  Contaminated air has often 
been cited as the cause of many epidemics in the early history of the world [1].  With the 
discovery of food, water, and arthropods as vectors for disease transmission, aerosol 
transmission was largely rejected [1].  However, the 1917 influenza pandemic highlighted the 
importance of aerosols as a mode of disease transmission [4].  It is hard to prove respiratory 
transmission of disease, though for certain infections, such as Severe Acute Respiratory 
Syndrome (SARS), it is generally accepted that disease transmission is due to aerosols or 
airborne droplets [1, 5]. 
There are three main classifications for organisms spread through respiratory 
transmission: obligate, preferential, and opportunistic [1, 6].  Organisms that are classified as 
obligate transmission are only spread through aerosol deposition in the lungs, such as 
tuberculosis [1, 6].  Preferential transmission includes organisms that are able to cause disease 
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through other means of transmission but are primarily spread through aerosols, such as influenza 
[1, 6].  Opportunistic aerosol transmission refers to organisms that usually infect hosts through 
other routes, but are able to cause disease if they are transmitted through aerosols, such as 
Francisella or anthrax [1, 6].   
A variety of microorganisms can cause disease through aerosols, though some are 
naturally communicable and others are artificially induced [6].  Cumulative naturally 
communicable respiratory infections account for the highest proportion of the global burden of 
disease, higher than HIV, tuberculosis, and cancer [5, 7].  Lung infections can be classified as 
either upper or lower respiratory infection, with lower respiratory infection having higher 
mortality and morbidity, and can be caused by bacteria, viruses, or fungi [6].  However, lung 
infections are not the only result of aerosol transmission.  Smallpox and measles are spread 
through droplets and aerosols, but uncomplicated cases of these viruses result in maculopapular 
rashes rather than respiratory infections [5].  Some pathogenic agents not traditionally known for 
respiratory transmission can also be infectious through artificially induced aerosols. Military 
endeavors in the U.S. during the 20th century included the development of an offensive 
biological weapons program with the intention of optimizing infectious agents for widespread 
aerosol distribution over enemy populations [6].  During this time mosquito borne viruses, such 
as Rift Valley Fever Virus or Venezuelan Equine Encephalitis Virus, were weaponized for 
aerosol dissemination [6].  The wide array of microorganisms that can be spread through 
aerosols and the range of clinical disease these microorganisms can cause highlight the need to 
study aerosol-acquired disease and the factors that can affect disease transmission. 
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1.2 AEROBIOLOGY  
Droplet nuclei are the dried out residuals of infectious droplets less than 5um in diameter that can 
remain suspended in air for long periods of time [3].  These droplets are thought to be the basic 
mechanism for aerosol transmission of disease as they are the major component of biological 
aerosols [3].  Aerobiology is the study of the dispersion of aerosolized microorganisms and their 
byproducts and the factors that can affect this dispersion, such as relative humidity and 
temperature [3, 6].  This term is used in both the real world setting and the laboratory setting.  
Often times, real world settings of aerobiology focus on the spread of fungal spores and pollen.  
In research settings, aerobiology also includes the study of the effects of these airborne 
biological agents, such as disease pathogenesis. 
Natural aerosol infection is dependent on a variety of uncontrollable factors that are 
largely dependent on the clinical course of disease, such as infectious dose and particle size.  
Such variables can contribute to differences in disease onset or pathogenesis which could 
therefore affect study design [8].  Thus, a controlled, experimental setting allows for a more 
rigorous study of aerosol-acquired disease [8].  
1.2.1 FDA Animal Rule  
In 2002, the Food and Drug Administration (FDA) Animal Efficacy Rule, termed Animal Rule 
for short, was authorized by Congress following the terrorist attacks on September 11, 2001 in 
response to the increased interest in the development of therapeutics and vaccines to combat 
potential bioterrorism [9, 10].  The Animal Rule allows the use of animals for efficacy testing of 
drugs or vaccines where human trials are not feasible or ethical, such as in cases where disease 
 4 
incidence is too low or sporadic to effectively test or the disease causes serious health 
complications in humans [10, 11].  Since the implementation of the Animal Rule, there have 
been few new therapeutics developed.  Pyridostigmine bromide and levofloxacin are FDA 
approved drugs for which new clinical uses have been found [9].  Cyanokit is a drug approved in 
Europe that has now been approved for use in the United States to treat cyanide poisoning [9, 
10].  Raxibacumab is the first novel therapeutic that has been developed under the Animal Rule 
for the treatment of inhalational anthrax [9]. 
Products developed under the Animal Rule must meet four main requirements: the 
pathophysiology of disease and mechanism of protection of the vaccine or drug must be well 
defined in the animal models in order to predict human response [9-12];  the desired effect must 
be shown in relevant animal models to predict the response in humans, which usually requires 
more than one animal model; [9-12] the animal study end point must correlate with the desired 
effect in humans, such as reduction in death or clinical disease due to the challenge agent; and 
there must be sufficient pharmacokinetic and pharmacodynamics data to determine an effective 
dose in humans.  It should be noted that clinical trials to demonstrate safety are still required. 
Though the FDA Animal Efficacy Rule was designed to help promote the development 
of drugs and vaccines to potential bioterrorism threats, the requirements do not make the process 
easier [9].  Hence, they have developed guides to aid researchers in the planning, development, 
and testing of drugs and vaccines using the Animal Rule.  To meet these requirements, the route 
of exposure of the agent and the route of administration of the drug or vaccine should be the 
same, and the dose of the challenge agent should be established to consistently reproduce disease 
similar in humans [10, 12].  Though ideally the challenge agent should be the same agent that 
causes disease in humans, the FDA recognizes that this is not always possible, such as with 
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smallpox.  In such instances, the FDA may allow closely related agents or animal model adapted 
agents.  Importantly, there should be enough data to prove that the disease pathogenesis is 
similar to human disease.  Other requirements for the Animal Rule can include the following: the  
immune response in the animal model must be sufficiently similar to the response in humans to 
predict protection; the natural history of the disease should be similar to human disease; there 
should be a clearly defined trigger for intervention to aid in determining when to administer 
vaccines or drugs to humans; and there should be sufficient animals used in critical studies to 
perform statistical analysis [10]. 
1.2.2 Aerosol Study Techniques  
There are three inoculation methods currently used in animal research to replicate respiratory 
disease transmission: intranasal, intratracheal, and aerosolization.  Each method has its strengths 
and shortcomings, but the results from these different types of techniques are not directly 
comparable due to potential variances in disease pathogenesis [13]. 
Intranasal inoculation procedures involve gradual administration of the inoculum into the 
animal’s nostrils [13].  Intratracheal inoculation is an invasive procedure to physically administer 
the inoculum through the test animal’s trachea [14].  Both intranasal and intratracheal inoculation 
deliver a bolus of liquid to the lungs which does not mimic a true aerosol exposure. Dispersal in 
the lungs may not be uniform after intranasal or intratracheal inoculations, with the majority of 
disease at the site of inoculation [15].  Doses can be higher than are required for inhalation [14].  
These factors may result in failure to achieve similar disease pathogenesis observed after aerosol 
exposure [13].   
 6 
Inhalation exposure of aerosolized viruses or bacteria is technically challenging and 
requires specialized equipment to produce aerosols from an inoculum and an air flow system to 
deliver the aerosolized inoculum to an exposure chamber containing the test animals [14, 15].  
The design and use of this type of equipment requires coordination between biological and 
engineering sciences to ensure successful and reproducible aerosol studies that are safe for the 
operator [8].  Smaller animals are not typically anesthetized while larger animals, such as 
nonhuman primates are anesthetized for the safety of the animal and personnel, which can alter 
the natural respiratory function of the animal.  Aerosol exposures may also lead to deposits of 
infectious agent in the fur of test subjects, which could be inhaled or ingested after the aerosol 
infection depending on the exposure chamber used, potentially altering the desired disease 
course.  Most experimental aerosol systems target a smaller, uniform particle size, allowing for 
better deposition of infectious agent in the lung, especially the lower respiratory tract. Aerosol 
generators are available that generate larger particle sizes to target the upper respiratory tract but 
these studies are the most challenging to undertake and have not been as well studied. Dosage, 
particle size, particle age, environmental temperature and humidity can all be measured, 
controlled, and analyzed to a limited degree with most experimental aerosol systems. A top-of-
the-line computer-controlled system, the AeroMP, is available at the University of Pittsburgh and 
allows for a high degree of monitoring and control of these environmental parameters. The 
control of these parameters allows for the study of how these factors affect microorganisms and 
their aerosol infectivity. 
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1.2.3 Biological Aerosol Exposure Systems 
The AeroMP, an automated aerosol management platform, is an exposure system used at many 
aerobiology research facilities around the world [16].  This system, shown in Figure 1, was 
developed at the United States Army Medical Research Institute of Infectious Diseases 
(USAMRIID) for use within a Class III Biosafety Cabinet [16, 17].  The platform was designed 
to withstand the repeated decontamination with paraformaldehyde gas or hydrogen peroxide 
vapors necessary for reuse of the aerosol equipment with different pathogens or animals [16].  
The AeroMP unit electronically monitors and in some cases can control several parameters that 
can influence aerosol exposure, such as relative humidity, exposure duration, and sampler 
pressure [16, 17]. 
An aerosol system for exposing animals to infectious agents consists of aerosol 
generators, exposure chambers, and aerosol sampling devices which can include a particle sizer 
[16, 17].  Depending on the aerosol generator employed, compressed air may be used to generate 
aerosol droplets [16].  These droplets may be diluted with additional air and dried to optimal size 
in the mixing tube before entering the exposure chamber [16].  Simultaneously, air is pulled from 
the exposure chamber using a vacuum pump creating a dynamic air flow to ensure newly 
generated particles pass through the chamber at a steady rate [16]. Based on USAMRIID’s 
aerosol studies, a steady-state air flow (equal input and exhaust flow rates) is established in the 
chamber set at a rate equal to 1 complete air change in the exposure chamber every 2 minutes. 
Wide varieties of aerosol sampling devices are used including impingers, gel filters, and particle 
sizers. In animal studies an impinger is typically used and is attached to the exposure chamber to 
continuously samples the aerosol throughout the experiment at a defined rate of exhaust based on 
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the design of the impinger and flow rate through the critical orifice [16].  This sample is then 
used to determine the aerosol concentration of the experiment [16]. 
 
Figure 1. Schematic of the AeroMP Exposure System 
Direction of airflow is indicated by the arrows.  The exposure system is enclosed within a Class III Biosafety 
Cabinet and is controlled by software on a laptop outside of the cabinet.  Compressed air enters the Biaera system, 
which releases a controlled flow of generator air and dilution air based on desired parameters.  The generator air 
flows through the aerosol generator creating aerosol particles, which then enter the mixing tube where the particles 
are dried to optimal size by the dilution air.  A vacuum pulls air through the exposure chamber to ensure a 
continuous flow of newly generated aerosol particles.  A bioaerosol sampler and/or particle sizer may be attached to 
the exposure chamber.  Reprinted from “ABSL-4 aerobiology biosafety and technology at the NIH/NIAID 
integrated research facility at Fort Detrick,” by M.G. Lackemeyer, Viruses, 6(1), 137-150. Copyright 2014 by 
P.B.Jarhling.  Reprinted with permission. 
1.2.3.1 Aerosol Generators 
In modern infectious aerosol studies, aerosol generators employ liquid media, rather than dry 
powders, to produce aerosols.  Dry powders containing infectious agents were commonly used 
during biological weapons research.  Thus, there is a concern for the potential “dual use” of data 
gained from dry powder aerosol for bioterrorist attacks.  Currently, the Collison nebulizer is the 
gold standard for use in aerobiology research, though there is a wide range of aerosol generators 
using different methodologies to produce aerosols available for use [18]. 
The Collison has become the standard for aerosol generation due to its low cost and easy 
maintenance, its relatively uniform and monodisperse particle distribution, and the small particle 
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sizes it generates (1 to 2 um in diameter), which are ideal for reaching the alveolar regions of the 
lungs in mammalian species [8].  The Collison utilizes Bernoulli’s principle to create aerosols 
from a liquid sample [18, 19].  Bernoulli’s principle states that the speed of a moving fluid, 
whether liquid or gas, increases as the pressure exerted by the fluid decreases [20].  Compressed 
air enters through the stem of the Collison and expands from the jets into the nozzle causing the 
liquid sample to be suctioned into the nozzle [18, 19, 21-23].  The fluid is sheared into small 
droplets by the air jets and is then expelled to impact against the inside of the jar [18, 19, 21-23].  
Over 99.5% of this sample is refluxed back into the jar to recirculate, while the remaining 
aerosol droplets are carried out of the nebulizer by the spent compressed air flow [18, 19, 23].  
The original version of the Collison was designed with three jets, but models with one jet, six 
jets, or 24 jets are now available.   
Prior studies have indicated that the 3-jet model has a higher aerosol efficiency than the 
1-jet model [24].  The 3-jet Collison cycles 200ml of sample every minute [19].  A 10ml sample 
will recirculate approximately 200 times over a ten minute aerosol.  This repeated cycling places 
mechanical stress on the microorganisms, potentially reducing the viability or virulence and thus 
the aerosol efficiency [22, 25].  The potential ‘battering’ of the infectious agent by the Collison 
may result in higher doses required to cause infection and/or disease in the animal although this 
speculation is largely theoretical.  This can make reproducibility of studies a concern if different 
stocks of microorganisms are used for each experiment.  While the process of aerosolization will 
always place mechanical stress on infectious agents, aerosol generators that use less sample but 
have an equivalent or better aerosol efficiency in the preferred particle size range would be 
desired as they could better ensure reproducibility by allowing the use of the same stock of the 
agent throughout several studies [25, 26].  
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A newly developed alternative to the Collison is the Blaustein Atomizing Module 
(BLAM).  This apparatus uses the same aerosolization method as the Collison to produce 
particles 0.7 to 2.5um in diameter, but it can be used in a single or multi-pass (recirculating) 
mode [27].  In the single pass atomization mode (SPA), the liquid media is externally introduced 
over a period of time into the nebulizing head where compressed air flow forces aerosol 
formation [27].  In multi-pass atomization mode (MPA), liquid is forced into the nebulizing head 
by the vacuum created by the air jets [27].  Unlike the Collison, droplets formed from 
atomization are expelled downwards to impact on the remaining liquid sample [27].  Small 
droplets impact with the liquid surface and make a 180 degree turn to be carried out of the 
atomizer while larger droplets collect on the surface of the liquid as they are too large make the 
turn [27].  Impacting the droplets over a liquid surface reduces the magnitude of force applied to 
the organisms compared to the Collison, hypothetically increasing the aerosol efficiency of 
viable organisms. 
While the Collison and BLAM were both designed for use in research settings, the 
Aerogen® Solo Aeroneb is a single use nebulizer used in clinical settings for drug delivery.  The 
nebulizer utilizes a palladium mesh that is 5mm in diameter and perforated with 1000 precision 
formed conical shaped holes [28].  Electricity is applied to the vibrational element, causing the 
mesh to vibrate 128,000 times per second [28].  The mesh draws the liquid through the 
perforations, acting as a micropump, to create a fine particle mist with particles ranging from 
1um to 5um in size [28].  The clinical use Aeroneb is not designed to be autoclaved and thus 
cannot be reused for multiple aerosol experiments. 
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1.2.3.2 Exposure Chamber 
The exposure chamber is the locus at which test animals are exposed to the aerosol.  While 
choice of exposure chamber will largely be dependent on the animal species and study needs.  
The differing types of exposure chambers affect environment factors, such as pressure, humidity, 
air flow, which could affect aerosol results.  Nose-only towers are designed to expose only the 
breathing zone of the test subjects and thus limit the potential for ingestion, dermal absorption, 
and other non-respiratory routes [29].  Despite this potential benefit, previous studies have 
indicated that even with the nose-only exposure, a variable percentage of the infectious aerosol 
enters the gastrointestinal tract through pulmonary clearing and subsequent swallowing [30].  
Other studies indicate the restraining required for nose-only exposure increases stress levels of 
the test animals, as measured by corticosteroid levels, and that acclimation to the restraints does 
not reduce the stress of the test animals [31].  The alternatives to the nose-only chambers are 
whole-body and head-only chambers.  As described in the name, the whole body chamber 
exposes the whole body of the animal and the head only chamber exposes just the head of the 
animal. 
1.2.3.3 Aerosol Sampler 
There are a variety of bioaerosol samplers available for use in aerosol research, including liquid 
impingers, impactors, and filters.  Similar to the nebulizer, the aerosol sampler is another device 
in the aerosol system that can reduce viability or virulence.  Thus, the choice of sampler should 
be considered to maximize the aerosol performance.  Prior studies indicate liquid impingers 
cause the least amount of damage to microorganisms, leading to their widespread use in 
aerobiology [32].  All glass impingers (AGIs) are the most common sampler used to collect 
airborne microorganisms [32].  This liquid impinger is designed to mimic the airway of the 
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human upper respiratory tract and consists of a glass jar and a curved glass tube [32].  Air is 
pulled through the AGI, forcing air from the exposure chamber into the curved tube [32].  The 
diameter of the tube narrows, creating a critical orifice (the point at which air flows through a 
narrow opening at Mach one speed) where the aerosol is impacted with and collected in a liquid 
media [32].  The impinger sample can then be used to determine the aerosol concentration, 
infectious dose, or other aerosol characteristics. 
1.2.4 Aerosol Performance 
Aerosol performance is measured in a variety of ways; however, the method for analysis is 
dependent on the goal of the experiment.  Clinical use nebulizers, for example, may focus more 
on nebulization time of drugs or ease of use.  In research settings, aerosol performance may 
focus on particle concentration and size or biological parameters, such as culturability [22].  
Determining the effect of aerosol generation on the virulence and viability of the microorganism 
of interest prior to exposure of animals is important to ensure accurate dose estimation and 
biological response [33].  
The spray factor, or aerosol dilution factor, is a commonly employed method for 
measurement of aerosol performance.  The spray factor needs to be determined for each aerosol 
exposure configuration and is expressed as the ratio of the aerosol concentration to the starting 
nebulizer concentration [8, 24, 26, 33].  This ratio allows for quality control between aerosol 
experiments with a specific agent as well as estimation of the starting concentration needed to 
reach a desired dose in an animal [8].  
Particle size, expressed as aerodynamic diameter, is another method to analyze aerosol 
performance.  The size of aerosol particles is especially important as it can affect the survival 
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time of the infectious agent as well as where in the respiratory tract the particle can reach [6].  
Generally, particles over 10 µm deposit in the upper respiratory tract, while smaller particles are 
able to penetrate deeper into the lower bronchial and alveolar spaces [1, 3, 16, 32].  
Microorganisms require contact with susceptible cell types to induce disease; thus, it is important 
in laboratory settings that nebulizers are able to produce aerosolized particles that are optimally 
sized to reach the desired location in the respiratory tract [6]. 
Another method to analyze aerosol performance that can be used to predict the dose 
delivered during an aerosol exposure is aerosol efficiency [34].  Aerosol efficiency characterizes 
the effect of artificial generation of aerosols on an organism and is expressed as the ratio of the 
actual aerosol concentration to the theoretical aerosol concentration [34, 35].  The actual aerosol 
concentration is determined from the titer collected in the bioaerosol sampler, and the theoretical 
concentration is determined as the amount of agent that was aerosolized by the aerosol generator 
[34]. 
1.2.5 Environmental Factors  
Similar to real world situations, environmental factors such as relative humidity and temperature 
can vary between aerosol exposures, potentially altering efficiency of aerosol transmission and 
thus aerosol performance [3, 24, 26, 32, 33]. Temperature and humidity levels might alter 
particle evaporation, potentially affecting particle size and subsequently survival of the agent and 
deposition in the respiratory tract. For example, epidemiological studies have suggested that 
Influenza A viruses have improved transmission in low absolute humidity seen in northern 
climates during winter, yet transmission in tropical climates is not affected [32, 36].  Other 
studies examining the effects environmental factors on microbial agents in research settings 
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indicate Francisella tularensis and Rift Valley Fever Virus have improved survival following 
aerosol generation in higher humidity [24, 26].  These studies highlight the need to characterize 
fully the effects of environmental factors on aerosol performance to achieve a standardized and 
reproducible system for animal exposures [24, 26]. 
1.3 ORGANISMS  
1.3.1 Francisella tularensis 
Tularemia is caused by a small, pleomorphic, gram-negative coccobacillus, Francisella 
tularensis [37].  This disease was first clinically observed in people that consumed rabbit meat in 
Japan in 1837 [38].  In the United States, tularemia was described in 1911 as a plague-like illness 
in ground squirrels in Tulare County, California [38].  Three years later, the first clinical case in 
the United States was seen in a butcher [37, 38].  There are currently four identified subspecies 
of F. tularensis: tularensis, holarctica, mediasiatica, and novicida.  Subspecies tularensis is 
highly virulent and is the dominant species found in the U.S.; subspecies holarctica is less 
virulent and is prevalent throughout European countries [37, 38].  Francisella is able to survive 
for long periods of time at low temperatures in soil, water, decaying animal carcasses, and other 
environments [37].  Francisella is classified as a category A biothreat agent due to its high 
infectivity, ease of dissemination, and ability to cause severe illness or death [38]. 
Every state in the United States, except Hawaii, has reported human cases of Francisella, 
with the majority of cases occurring in the Midwest and southwest regions [37, 39].  In Europe, 
tularemia is also widespread, with the highest incidence in Scandinavian countries and those of 
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the former Soviet Union [37].  Prior to 2015, an average of 120 cases of tularemia was reported 
annually in the United States; however, 175 cases of tularemia were reported in a 9-month period 
during 2015 [40].  This recent outbreak led to 48 hospitalizations and one death [40]. 
Francisella tularensis is able to infect humans through the skin, mucosal membranes, 
gastrointestinal tract, and the lungs, each producing a different disease pathogenesis [37, 38].  
Handling infected animals, or the bite of an infected arthropod, results in an ulceroglandular 
disease characterized by cutaneous ulcers [38].  Ingestions of contaminated food or water may 
result in an oropharyngeal disease characterized by ulcers on the tonsils, pharynx, and soft pallet 
[38].  Pneumonic tularemia is the most acute form of disease and results from inhalation of 
contaminated air [37, 38].  It is characterized by hemorrhagic inflammation of the airways and 
systemic dissemination, with the spleen and liver being the primary location of pathological 
changes [37, 38].  Tularemia can be difficult to diagnose; blood tests, cultures, or PCR are used 
in conjunction with clinical symptoms for diagnosis [37, 40].  Though the incidence of tularemia 
is generally low, there is a concern that F. tularensis will be used in a bioterrorism event.  While 
relatively easy to treat, rapid diagnostic tests are not widely available, so detection of intentional 
release relies on recognition by public health authorities [37].   
Streptomycin and chloramphenicol are the licensed drugs for treatment of tularemia, 
though several other antibiotics used off-label have been shown to be effective [37, 38, 40].  
These include gentamicin, doxycycline, ciprofloxacin, and tetracycline [37, 38, 40].  Patients 
treated with chloramphenicol and tetracycline sometimes relapse [38].  Antibiotic therapy is 
usually prolonged, but when administered properly it can reduce fatalities to about 2%.  
Currently there is no FDA approved vaccine for F. tularensis.  A live attenuated vaccine derived 
from a virulent F. tularensis subspecies holarctica strain developed by the Soviet Union was 
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acquired and tested in the 1960s by the United States and is used to protect at-risk laboratory 
workers as an investigational new drug [37, 38].  This vaccine reduced the incidence of 
inhalation tularemia, but not ulceroglandular disease, though symptoms were often reported as 
milder [37, 38, 41].  Despite this reduction in laboratory cases, in a study involving human 
subjects, the vaccine did not protect volunteer recipients against higher aerosol challenge doses 
of virulent F. tularensis [37, 41]. 
1.3.2 Influenza 
1.3.2.1 Seasonal Influenza 
Influenza viruses are negative sense single stranded RNA, enveloped viruses of the family 
Orthomyxoviridae [42].  There are three types of influenza viruses, A, B, and C, but only types A 
and B are associated with significant disease and mortality [42, 43].  Influenza A viruses are able 
to infect a wide range of animal species, resulting in the seasonal antigenic drift and epidemic 
causing antigenic shift [42, 43].  Influenza A viruses can be subtyped based on the hemagglutinin 
and neuraminidase proteins on the surface of the virion [42, 43].  There are 16 HAs proteins and 
9 NA proteins.  Despite this diversity only H1N1, H1N2, H2N2, and H3N2 have caused 
pandemics [42].  Influenza B viruses do not undergo antigenic shift and thus do not have the 
same epidemic or pandemic potential of Influenza A viruses [42, 43]. 
Influenza infections peak during the winter months and primarily affect children and the 
elderly.  In the United States, seasonal influenza results in more than 200,000 hospitalizations 
and 30,000 deaths annually [43].  While pandemics are much rarer, with only 11 influenza 
pandemics occurring during the past 300 years, the effects are much more devastating due to 
higher mortality rates and the lack of effective vaccines or treatment [2, 42, 43].  The 1918 
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Spanish Flu pandemic was responsible for 50 to 100 million deaths worldwide; the 1957 Asian 
Flu pandemic was responsible for more than 1 million deaths; the 1968 Hong Kong Flu 
pandemic was responsible for more than 700,000 deaths [42, 43]. 
Generally, influenza is spread person to person through respiratory droplets and aerosols, 
but can also be spread through fomites [42, 43].  Infectious particles must come in contact with 
respiratory epithelial cells in order to cause disease.  People infected with influenza usually 
exhibit fever, a dry cough, nasal congestion, headache, sore throat, and malaise [43].  Infection is 
localized to the lung tissue, but in severe cases the virus can disseminate and cause 
encephalopathy, pericarditis, and rhabdomyolysis [43].  Influenza infections can be diagnosed 
with viral cultures, reverse transcriptase PCR, or antigen testing in conjunction with clinical 
symptoms [43].  Diagnosis can allow for viral therapy and avoid the use unnecessary use of 
antibiotics; however, most patients fail to seek medical care or have laboratory tests to confirm 
infection [43]. 
Several antiviral drugs are currently licensed to treat influenza in the United States [43].  
Amantadine and Rimantadine block the M2 viral protein channel; oseltamivir and zanamivir are 
neuraminidase inhibitors [43].  These drugs are most effective when administered within 48 
hours of symptoms and can reduce the duration and severity of illness, though antiviral 
resistance has emerged [43].  The best method to mitigate the effects of season influenza 
epidemics is to vaccinate against influenza [43].  Due to antigenic drift, the influenza vaccine 
components change annually based on the predicted strains for the upcoming influenza season 
[43].  Predicting the season’s strain is not an exact science, and thus some years the vaccine may 
not be effective against influenza infection [43].  Current technology for developing influenza 
 18 
vaccines is slow, hindering the ability to develop effective vaccines in the event of a poorly 
predicted vaccine or a pandemic as occurred in 2009 [43]. 
1.3.2.2 Highly Pathogenic Avian Influenza 
Highly pathogenic avian influenza (HPAI) refers to strains of influenza that are extremely 
infectious and cause deadly disease in poultry [44].  HPAI was first reported in 1878 in Italy, but 
the virus was not identified as an Influenza A virus until 1955 [44].  Since the isolation of the 
virus, there have been 18 outbreaks of HPAI, 17 in domestic poultry and 1 in wild seabirds [44].  
There have been numerous instances of direct transmission of highly pathogenic avian influenza 
to humans, though it is important to note the ‘highly pathogenic’ connotation denotes 
pathogenicity in poultry not humans [44].  For example, so-called low pathogenic avian 
influenza (LPAI) strains can be highly pathogenic in humans. One of the first outbreaks of HPAI 
was in 1997 in Hong Kong where 18 people were hospitalized due to H5N1 with six deaths [42-
44].  While HPAIs cannot maintain sustained human-to-human transmission there is a concern 
that an HPAI will recombine with a human-adapted influenza virus causing to an antigenic shift 
that could cause a pandemic in humans [44, 45].  Another notable outbreak was in 8 family 
members in Sumatra, seven of which died, where the World Health Organization reported 
human-to-human transmission may have occurred [46].   
 While seasonal influenza infections are generally localized to the respiratory tract, highly 
pathogenic avian influenzas can cause severe systemic disease in humans.  In the case of the 
Hong Kong outbreak of H5N1 in 1997, patients experienced fever, pneumonia, and acute 
respiratory distress syndrome [47].  Studies have shown that many strains of highly pathogenic 
avian influenza are susceptible to neuraminidase inhibitors, but resistant to the adamantine drugs 
[45].  Since a variety of HPAI strains have been transmitted to humans and transmission is not 
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sustained among humans, there is currently no vaccine to prevent HPAI infection in humans as it 
would be difficult to predict which particular strain of HPAI will cause an epidemic [44, 45].  
1.3.3 Rift Valley Fever Virus 
Rift Valley Fever Virus (RVFV) is a Phlebovirus of the family Bunyaviridae first identified 
during an outbreak among lambs in Kenya in 1930 [48, 49].  This negative sense, single stranded 
RNA virus is chiefly transmitted by mosquitoes, but can also be spread by ticks, flies, 
contaminated blood or tissue, and aerosols [48, 49].  RVFV primarily affects domestic animals, 
such as cattle, sheep, and camels, and massive abortion events, termed abortion storms, are the 
characteristic mark of outbreaks [26, 48].  No documentation reports human-to-human 
transmission of RVFV, but during the time of offensive bioweapons research, the United States 
was able to weaponize this virus.  Due to the potential devastating effects in agriculture and the 
human population, RVFV is considered a high priority select agent by both the United States 
Department of Agriculture (USDA) and the Department of Health and Human Services [50]. 
Since its discovery, RVFV outbreaks among ruminants have occurred throughout Africa.  
The first recorded outbreak in 1930 resulted in 100,000 deaths and 500,000 abortions among 
sheep in South Africa [51].  Outbreaks have also occurred in Namibia, Zimbabwe, Zambia, 
Mozambique, Sudan, Egypt and Mauritania [51].  In September 2000, Rift Valley Fever was 
detected in Middle East [51].  The exact mechanism of spread of Rift Valley Fever is not known, 
but could be dependent on a variety factors such as mosquito ecology, climate change, and 
globalization.  Mosquitoes capable of transmitting RVFV inhabit nearly every continent and 
increasing global temperature allows these mosquitoes to spread into previously virgin areas, 
potentially bringing Rift Valley Fever Virus to new regions [48].  Airplanes or ships may carry 
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infected arthropods to previously unaffected areas [48].  Infected individuals or livestock may 
carry the virus into new regions; [48]. if a vector competent at transmitting the virus is present in 
the area, the virus may become endemic to the area.   
Rift Valley Fever Virus enters the human population during outbreaks of domestic 
ruminants [49].  The density of infected domestic animals increases the likelihood that an 
infected mosquito will feed on humans in close proximity.  The virus is also transmitted to 
humans through contaminated body fluids, which can occur during birthing or slaughtering if 
proper protective equipment is not worn [49].  The majority of infected individuals are 
asymptomatic, but a small proportion exhibit disease [49].  Most symptomatic individuals show 
signs of influenza like symptoms, hepatitis, photophobia, or retro-orbital pain [49].  Severe cases 
of Rift Valley Fever infection can develop retinitis, encephalitis, and hemorrhagic fever [49].  In 
the absence of severe clinical manifestations, Rift Valley Fever is difficult to recognize.  
Laboratory diagnoses of RVF infection can be done using virus isolation, antigen detection, or 
reverse transcriptase PCR, though is typically limited to biocontainment facilities. 
Currently there is no specific antiviral treatment for Rift Valley Fever.  Treatment 
includes supportive care and Ribavirin, which is a nucleoside inhibitor that stops viral RNA 
synthesis and viral mRNA capping [49].  Public health efforts to prevent Rift Valley Fever 
outbreaks focus on mosquito control and the use of personal protective equipment by those with 
potential occupational exposure to the virus [48].  To prevent the loss of thousands of animals 
and potentially humans, a killed RVF vaccine and a live attenuated RVF vaccine have been used 
in domestic sheep and cattle in Africa and Egypt [48].  Reports indicate the live attenuated 
vaccine has caused vaccinated sheep to abort, indicating the virus in this vaccine can revert to its 
virulent form [48].  Though not FDA approved, a formalin inactivated vaccine exists for use in 
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humans, but it is expensive to produce, limiting its use to veterinarians and laboratory workers 
[48]. 
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2.0  SPECIFIC AIMS 
Reliable and reproducible aerosol experiments require a full understanding of the effects of 
equipment selection and environmental factors on aerosolization of pathogens and their 
subsequent disease. The goal of this study is to investigate potential alternatives to the Collison 
for aerosol generation in research use with regard to both viruses and bacteria.  The Collison is 
the aerosol generator of choice for research studies because it is well characterized and produces 
high-density aerosols in the optimal size range for aerosol studies.  However, the mechanism of 
nebulization in the Collison may cause damage to the organism [22].  The BLAM and the 
Aeroneb are newer aerosol generators with little data available on the ability to create 
bioaerosols and their effect on viability.  Due to the mechanism of aerosol generation, the BLAM 
and Aeroneb aerosol generators are hypothesized to have improved aerosol performance 
compared to the Collison.  Characterizations of these aerosol generators will allow for optimal 
selection of equipment to produce the desired response in animal models. 
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2.1 AIM 1: TO COMPARE THE AEROSOL PERFORMANCE OF THE BLAM AND 
THE AERONEB WITH THE STANDARD 3-JET COLLISON 
Aerosol performance will be compared using the spray factor, the aerosol efficiency, and particle 
size, using one bacterium (F. tularensis) and two negative-strand RNA viruses (influenza and 
Rift Valley Fever virus) with the different aerosol generators.  The goals of this aim are to: 
a. Determine the optimal spray factor for each aerosol configuration using 
fluorescein salt as a surrogate for microorganisms as the salt cannot be damaged 
by aerosolization. 
b. Determine the spray factor, particle size, and aerosol efficiency for each aerosol 
generator with different exposure chambers. 
2.2 AIM 2: TO CHARACTERIZE ENVIRONMENTAL FACTORS AFFECTED BY 
THE CHOICE OF AEROSOL GENERATORS AND THEIR EFFECT ON PATHOGEN 
VIABILITY. 
Relative humidity, temperature, and other aerosol parameters will be analyzed to determine if the 
factors are affected by choice of aerosol generator.  The goals of this aim are to: 
a. Determine the relative humidity and temperature ranges the different aerosol 
generators produce. 
b. Determine if relative humidity and temperature, or other aerosol parameters, 
affect the viability of pathogens during aerosolization. 
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
All aerosol experiments for this study were performed in a class III biological safety cabinet 
within the dedicated Aerobiology Suite in the University of Pittsburgh Regional Biocontainment 
Laboratory (RBL).  Powered air purifying respirators (PAPRs) were worn for respiratory 
protection during work with H5N1 and RVFV, and all work with these viruses was conducted at 
BLS3 conditions in class II biosafety cabinets in the RBL, using Vesphene IIse (diluted 1:128, 
Steris Corporation, cat. #646101) for disinfection.  Spatial and temporal separation was 
maintained between H5N1 and all other infectious agents.  Work with F. tularensis LVS strain 
and seasonal influenza was conducted at BSL2+ conditions in a class II biosafety cabinet using 
10% bleach or Vesphene IIse (1:128) for disinfection. 
3.2 FRANCISELLA TULARENSIS 
All Francisella tularensis aerosols used live attenuated vaccine (LVS) strain Francisella 
tularensis obtained from Jerry Nau.  LVS stock was grown on August 7, 2008 and stored at -
80°C. 
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3.2.1 Culture Methods 
LVS was grown on Cysteine Heart Agar (CHA; BD DifcoTM, cat. #247100 and BD BBLTM, cat. 
#212392) for two days at 37°C, 5% CO2.  Broth cultures were set up with 0.5mls of bacteria 
suspended in 1X Phosphate Buffered Saline (PBS) at an optical density of 0.06 to 0.08 and 
24.5mls of Brain Heart Infusion (BHI; BD BBLTM, cat. #211059) broth, supplemented with 2.5% 
ferric pyrophosphate and 1.0% L-Cysteine hydrochloride, in a filter top, baffle bottomed flask.  
The cultures were incubated at 37°C in an orbital shaker at 200rpm and harvested between 15 to 
18 hours to ensure the bacteria was in the logarithmic growth phase [24].   
3.2.2 Concentration determination 
Concentration of LVS was determined by colony counts on CHA.  Tenfold serial dilutions of 
LVS aerosol samples were prepared in 1X PBS.  A multichannel pipette was used to dispense 
10µl of 5 consecutive dilutions to the top of a CHA plate held at a 45° angle.  The samples were 
allowed to drip down the plate, ensuring no sample paths crossed.  The plates were then placed 
agar side up to all the samples to air dry.  All plated dilutions were repeated in duplicate or 
triplicate.  Once dry, the CHA plates were inverted and incubated at 37°C/5% CO2 for two days.  
Dilutions with 15-100 colonies were chosen for titer calculations. 
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3.3 INFLUENZA 
Influenza A/PR/8/34 (H1N1), Influenza A/Syd/5/37 (H3N2), Influenza A/Ca/4/09 (H1N1), and 
Influenza A/Vietnam/1203/04 (H5N1) were used for aerosol experiments.  Influenza A/PR/8/34 
was obtained from Rich Webby and Influenza A/Syd/5/37 was obtained from Dr. Mickey Corb; 
both were propogated in MDCK cells.  Influenza A/Ca/4/09 was obtained from Biodefense and 
Emerging Infectious Resources and propagated in MDCK cells or chicken eggs.  H5N1 stock 
was propagated in MDCK cells or chicken eggs and obtained from the Centers for Disease 
Control and Prevention.  Temporal and spatial separation of all strains of influenza was 
maintained throughout the experiments.   
3.3.1 Determining Concentration 
Influenza virus titer was determined by standard TCID50 or plaque assay using Madin-Darby 
Canine Kidney Epithelial (MDCK) cells.  MDCK cells (ATCC CCL-34) were cultured in 
DMEM-10 (Dulbecco’s Modified Eagle’s Medium with 10% heat inactivated fetal bovine 
serum, 1% penicillin/streptomycin, and 1% HEPES).  Cells were passaged at 90% confluency 
using 1X PBS to wash the cells and 0.25% trypsin/EDTA to dissociate the cells from the tissue 
culture flask.  Trypsin/EDTA was neutralized with DMEM-10 at a ratio of 1:5, and cells were 
passaged into a new flask with fresh DMEM-10.  Cultured cells were incubated at 37°C/5% CO2 
between passages. 
For TCID50s, MDCK cells were seeded into a flat bottomed sterile 96 well plate at a 
concentration of 3.0e105 cells/ml and incubated at 37°C/5% CO2 overnight until 95% confluent.  
Tenfold serial dilutions of influenza aerosol samples were prepared in Viral Growth Medium 
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(VGM; Dulbecco’s Modified Eagle’s Medium, 2.5% of 7.5% bovine serum albumin fraction V, 
1% penicillin/streptomycin, 1% HEPES buffer, and 0.1% TPCK trypsin).  Medium was removed 
from cells and replaced with 150µl of VGM.  Five wells in one row were infected with 100µl 
each of one dilution.  This was repeated for each row, with the first row receiving undiluted 
sample and the last row receiving the lowest dilution.  Each well of the 6th column received 
100µl of VGM to act as a control.  The plates were incubated at 37°C/5% CO2 for 48 hours.  
Cells were then examined under a microscope for cytopathic effect (CPE) as compared to the 
controls.  Each well was scored as positive or negative for CPE.  Viral titers were then calculated 
using the method described by Reed and Muench  [52].. 
 For seasonal influenza plaque assays, MDCK cells suspended in DMEM-10 were seeded 
into 6-well tissue culture plates and incubated at 37°C/5% CO2 overnight until 95% confluent.  
Tenfold serial dilutions of influenza aerosol samples were prepared in VGM.  Medium was 
removed from the cells and 500µl of inoculum was added to each well; each dilution was 
repeated in duplicate.  Plates were incubated at 37°C/5% CO2 for 1 hour.  After incubation, 
inoculum was removed from the wells and a 1% nutrient overlay (2X Modified Eagle Medium, 
BSA, penicillin/streptomycin, 2% agarose) was added.  The overlay was allowed to polymerize 
and then the plates were incubated at 37°C/5% CO2 for 3 to 5 days depending on strain.  Plates 
were fixed with 2mls of 37% formaldehyde for at least 2 hours.  The formaldehyde was drained 
and the agar plugs were removed from the wells.  The cell monolayer was stained with a 0.1% 
crystal violet stain to visualize plaques.  Wells with 15 to 100 plaques were counted for titer 
calculations. 
 H5N1 plaque assays were performed in the same manner as seasonal influenza plaque 
assays with the following changes: 800µl of inoculum was used instead of 500µl; following the 
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addition of inoculum, the plates were incubated at 4°C for 10 minutes, then incubated at 
37°C/5% CO2 for 50 minutes; a 0.9% nutrient overlay was used instead of a 1.0% nutrient 
overlay. 
3.4 RIFT VALLEY FEVER VIRUS 
Rift Valley Fever Virus (RVFV) aerosols used strain ZH501, an isolate from patient 501 during 
the 1977 outbreak.  Recombinant RVFV was obtained from Barry Collins (CDC, Ft. Collins, 
CO) and propagated in Vero E6 cells.   
3.4.1 Sample Preparation and Concentration Determination 
All Rift Valley Fever Virus samples and media for AGI-30s were prepared by the Amy Hartman 
laboratory group.  RVFV titer was determined by standard plaque assay using Vero E6 cells.  All 
Rift Valley Fever Virus plaque assays were completed by Dr. Amy Hartman’s laboratory. 
3.5 AEROSOL SETUP 
3.5.1 Aerosol Exposures 
The AeroMP from Biaera Technologies (Hagerstown, MD) was used to monitor, record, and 
modulate aerosol parameters during aerosol experiments. Aerosol experiments consisted of three 
to five runs of one aerosol setup with one agent, ten minutes in length.  These experiments were 
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repeated in at least triplicate on different days to account for normal variance between aerosol 
experiments.  The airflow parameters of the aerosol experiments were programmed to do one 
complete air change in the exposure chamber every two minutes. 
3.5.2 Aerosol Generators 
Three aerosol generators were used in these studies: the Collison, the single use Aeroneb, and the 
BLAM (Figure 2).  The Collison was calibrated using the Gilibrator 2 (SensidyneTM GilianTM) 
before each aerosol to ensure an air flow of 7.5 ± 0.25 L/min; the BLAM and Aeroneb did not 
require air flow checks.  The Collison and BLAM were autoclaved at 121°C for 30 minutes prior 
to each aerosol experiment; the Aeroneb Solo is a single use device and is shipped in sterile 
packaging.  The BLAM was assessed in single-pass atomization mode using a programmable 
syringe pump (Model no. NE-1000, New Era Syringe Pump, Inc).  The syringe pump was 
programmed to dispense sample at a rate of 1ml per minute into the BLAM. 
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Figure 2. Aerosol Generators 
Image of the three aerosol generators compared in this experiment: A) The Collison, B) The BLAM, C) Aeroneb. 
 
Table 1 Flow Rate and Pressure of Aerosol Generators 
Pressure
Collison 7.5 L/min 26-30 PSIG
*PSIG per square inch gauge
BLAM 8.0 L/min 13-15 PSIG
Aeroneb 0.0 L/min 0 PSIG
Aerosol 
Generator Flow Rate
 
 
On the day of the aerosol experiment, the overnight LVS broth culture was harvested and 
diluted with additional BHI to reach a total volume of 45 or 65ml.  Frozen (-80°C) seasonal 
influenza stock was diluted 1:10 or 1:100 with VGM.  H5N1 stock was diluted with VGM to 
reach the necessary concentration to reach a specific target dose.  Rift Valley Fever Virus was 
diluted 1:10 or 1:100 with equal parts D2 (Dulbecco’s Modified Eagle’s Medium with 2% fetal 
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bovine serum, 1% penicillin/streptomycin, 1% L-glutamine) and antifoam solution (40µl 
antifoam, 80µl glycerol, and 100µl HEPES) for aerosol experiments. 
3.5.3 Aerosol Sampling 
Bioaerosol sampling was achieved using the all glass impinger-30 (AGI-30) calibrated with the 
Gilibrator to ensure an airflow of 6.0 ± 0.25 L/min (figure).  For LVS aerosols, 10ml of BHI 
broth and 40µl of antifoam A (Fluka, cat. #10794) was added to each AGI-30.  For influenza 
aerosols, 10ml of VGM and 80µl of antifoam was added to each AGI-30.  For Rift Valley Fever 
Virus, 10ml of D2 and 40µl of antifoam was added to each AGI-30.  Particle size was 
determined using the Aerodynamic Particle Sizer Spectrometer (APSTM) from TSI, Inc. 
(Shoreview, MN). 
3.5.4 Exposure Chambers 
Four different exposure chambers were used in these studies shown in Figure 3: the nonhuman 
primate head-only chamber (NHP HO), the ferret whole-body chamber (FWB), the rodent 
whole-body chamber (RWB), and the rodent nose-only tower (NOT).  Table 2 summarizes the 
volume of the exposure chambers and the programmed flow rate used for aerosol experiments. 
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Figure 3.  Exposure Chambers 
Image of three of the different exposure chambers used in this experiment: A) NOT, B) FWB chamber, and C) NHP 
HO chamber.  The RWB chamber (not shown) is similar in design to the FWB chamber but has a smaller volume.  
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Table 2 Chamber Air Volumes and Aerosol Flow Rate 
22.0 L/min
16.0 L/min
Volume
12 L
39 L
44 L
32 L
Flow Rate
8.0 L/min
19.5 L/min
Chamber
Rodent Nose-only Tower
Rodent Whole-body Chamber
Ferret Whole-body Chamber
NHP Head-only Chamber
 
 
The Collison and Aeroneb were compared for aerosolization of LVS in the nose-only 
tower and the rodent whole-body chamber.    For influenza, the Collison and the Aeroneb were 
compared in the nose-only tower, the ferret whole-body chamber, and the nonhuman primate 
head-only chamber.  Aerosol performance of Rift Valley Fever Virus between the Collison and 
the Aeroneb was compared in the rodent whole-body chamber.  The BLAM was designed for use 
with the NOT, and thus was only tested with LVS and seasonal influenza. 
3.6 AEROSOL PERFORMANCE 
3.6.1 Spray Factor and Aerosol Efficiency 
Aerosol performance between nebulizers was compared using the spray factor (SF) and aerosol 
efficiency.  Aerosol generator and AGI-30 titers were used for SF and aerosol efficiency 
calculations.  The SF is the ratio of the aerosol concentration to the starting aerosol generator 
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concentration.  Aerosol efficiency is the ratio of the true aerosol concentration to the theoretical 
aerosol concentration.  SF and aerosol efficiency were calculated as follows: 
 
 
where: 
 
 
In the equation V is volume, Q is flow rate, and Texp is the time of the exposure. 
3.6.2 Log Reduction in SF Due to Loss of Viability 
Fluorescein salt (Sigma, cat. #F6377) was added to some aerosol experiments to be used as an 
indicator of ideal spray factor given natural loss.  In fluorescein salt experiments, 0.1mg of 
fluorescein salt was dissolved in 1ml of ddH2O.  Log reduction was then calculated as follows: 
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3.7 STATISTICAL ANALYSIS 
GraphPad Prism® 6 was used to create all spray factor figures and to perform two-sided Mann-
Whitney U tests to compare the spray factor and aerosol efficiency between nebulizers.  This 
nonparametric test was chosen due to the non-normal distribution of results and the high 
frequency of outliers. 
STATA was used to perform a multiple linear regression to determine if collected 
environmental parameters, specifically chamber relative humidity, temperature, and sampler 
pressure, affect aerosol performance.  Temperature and humidity were included since prior 
studies indicate aerosol performance of certain pathogens are affected by these parameters.  
Sampler pressure (pressure in the AGI) was included due to observations regarding aerosol 
performance potentially related to sampler pressure. 
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4.0  RESULTS 
4.1 AEROSOL PERFORMANCE 
The ‘gold-standard’ Collison nebulizer may be overly harsh when aerosolizing pathogens. This 
could raise the nebulizer concentration needed to achieve a desired challenge dose in animal 
models and may affect virulence and host response, raising the dose required to cause morbidity 
and mortality in animal models. Other nebulizers might achieve better viability of pathogens in 
experimental aerosols, thereby lowering the concentration needed to achieve a desired dose in 
animal challenge studies. The goal of these studies was to compare performance of two 
alternative aerosol generators, the BLAM and the Aeroneb, to the Collison. Both produce 
particles in the same general size range as the Collison (between 1-5 μm MMAD), and such 
aerosol particles should be capable of reaching the deep lung. Aerosol performance of the 
aerosol generators was evaluated using spray factor (SF) and aerosol efficiency (AE).  Aerosol 
performance of these nebulizers was further evaluated in different exposure chambers and using 
both viruses and bacteria to evaluate whether differences seen were specific to a particular 
chamber or pathogen.  
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4.1.1 Francisella tularensis  
The different nebulizers were first assessed by aerosolizing F. tularensis (LVS) into two 
different aerosol chambers, the nose-only tower (NOT) and rodent whole body chamber (RWB). 
Aerosol exposures were ten minutes in length, and aerosol samples were collected in 10mls of 
BHI in AGIs.  Nebulizer and AGI concentrations were determined by plating serial dilutions on 
CHA plates.  Table 3 summarizes the SF results of each aerosol generator in each exposure 
chamber.  In the NOT, the Collison had the highest average SF (6.38E-07) compared to the 
BLAM (1.15E-07) and the Aeroneb (1.01E-08).  The coefficient of variation (CV) was highest in 
the BLAM (78.8%), followed by the Collison (62.1%) and the Aeroneb (27.8%), indicating the 
Aeroneb performance had better reproducibility in the NOT.  In the RWB chamber, the Aeroneb 
had the higher average SF (4.70E-08) compared to the Collison (2.98E-09).  The CV for the 
Collison was 99.8%, while it was 153.2% for the Aeroneb.  Figure 4 shows the spray factors of 
LVS in the NOT and the RWB using the BLAM, Aeroneb, and Collison.  Based on a two-sided 
Mann-Whitney U test, the SF in the NOT was significantly different between the Collison and 
the BLAM (p-value<0.0001) and the Collison and the Aeroneb (p-value<0.0001), but the mean 
SF indicates the Aeroneb and the BLAM did not outperform the Collison in Aerosol generation.  
In the RWB chamber, the SF was significantly different between the Collison and the Aeroneb 
(p-value=0.0004), with the Aeroneb achieving better aerosol performance. 
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Table 3 Summary of SF Results for LVS Aerosols 
NOT RWB
153.21%
SD 3.961E-07 9.074E-08 2.807E-09 2.98E-09 7.21E-08
CV 62.07% 78.77% 27.82% 99.80%
4.70E-08
Collison BLAM Aeroneb Collison Aeroneb
Mean 6.381E-07 1.152E-07 1.009E-08 2.98E-09
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Figure 4. Spray Factor of LVS is Higher with the Collison in the NOT and Higher with the Aeroneb in the 
RWB Chamber 
The Collison is represented by red symbols, the BLAM by green symbols, and the Aeroneb by blue symbols.  Error 
bars represent the median and interquartile range.  In the NOT, the SF is significantly different between the Collison 
and the BLAM (p-value<0.0001) and the Collison and the Aeroneb (p-value<0.0001).  In the RWB chamber, the SF 
was significantly different between the Collison and the Aeroneb (p-value=0.0004).  
 40 
Fluorescein salt was added to some aerosol experiments to determine the theoretical 
spray factor possible if no damage occurred to organisms.  Table 4 summarizes the log reduction 
in SF between the fluorescein salt and LVS.  In the NOT, the Collison resulted in a 1.44 log 
reduction in LVS SF (compared to fluorescein), the BLAM resulted in a 2.16 log reduction in 
LVS SF, and the Aeroneb resulted in a 2.85 log reduction in SF.  In the RWB chamber, the 
Collison resulted in a 3.61 log reduction in SF, while the Aeroneb resulted in a 3.08 log 
reduction.  Figure 5 shows a graphical representation of fluorescein SF compared to LVS SF 
with each aerosol generator in the NOT and the RWB chamber.  The difference in SF between 
Fluorescein and LVS was significant for the Collison (p-value=0.0079), BLAM (p-
value<0.0001), and Aeroneb (p-value=0.0006) in the NOT and for the Collison and Aeroneb in 
the RWB chamber (p-value<0.0001 for both). 
 
Table 4 Log Reduction in Spray Factor for LVS in the NOT and the RWB Chamber 
Collison 8.14E-06 2.01E-09 3.61
3.088.12E-099.74E-06Aeroneb
Aeroneb 7.08E-06 1.01E-08 2.85
Fluorescein 
Median SF
LVS Median 
SF
Log 
Reduction
RWB
Aerosol 
Generator
Collison 1.50E-05 5.40E-07 1.44
BLAM 8.35E-06 5.74E-08 2.16
Median 
Fluorescein SF
Median LVS 
SF
Log 
Reduction
Aerosol 
Generator
NOT
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Figure 5.  Significant Decrease in LVS Viability with All Aerosol Generators 
Red symbols represent the Collison, green symbols the BLAM, and blue symbols the Aeroneb.  Error bars represent 
the median and interquartile range.  Fluorescein salt SF represents the maximum achievable SF for each aerosol 
generator, while LVS SF represents the actual SF achieved using a live bacterium, LVS. 
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Aerosol efficiency of each aerosol generator is summarized in Table 5.  In the NOT, the 
Collison had the highest efficiency (1.598%), followed by the BLAM (0.639%) and the Aeroneb 
(0.035%).  In the RWB chamber, the Aeroneb (0.108%) had the higher aerosol efficiency than 
the Collison (0.012%).  The Aeroneb aerosol efficiency was significantly different from the 
Collison in both the NOT and the RWB chamber (p-value<0.0001).  
 
Table 5 Aerosol Efficiency of LVS in the NOT and RWB Chamber 
*Based on a two-sided Mann-Whitney U test
**Signficant results in bold
NOT
RWB
Aerosol 
Generator
Median Aerosol 
Efficiency P-value
Collison 0.012%
Aeroneb 0.108% <0.0001
Collison 1.598%
BLAM
Aeroneb
0.639%
0.035%
0.031
<0.0001
 
 
4.1.2 Influenza 
Aerosol performance of seasonal influenza A viruses was assessed in the rodent nose-only tower 
(NOT), the ferret whole-body (FWB) chamber, and the nonhuman primate head-only (NHP HO) 
chamber.  Differences in SF between different Influenza A subtype viruses were also evaluated 
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(Figure 6).  There was no significant difference between the SF of H3N2 and H1N1 with the 
Collison in both the FWB and the NHP HO chambers.  However, when using the Aeroneb there 
was a significance difference between the SF of H3N2, H1N1, and H5N1 (p-value=0.0005) in 
the NHP chamber, based on a Kruskal-Wallis test.  Dunn’s multiple comparison analysis reveals 
the SF of H3N2 is significantly different from the SF of H1N1 and H5N1, but there is no 
difference between the SF of H1N1 and H5N1. Due to limitations in the H5N1 stock available, I 
did not evaluate aerosolization of H5N1 with the Collison in either the NHP or the FWB 
chamber. 
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Figure 6. Spray Factor of Influenza is Similar Between Strains with the Collison, but is Significantly Different 
with the Aeroneb 
Several subtypes of Influenza A were used to compare aerosol generators.  The Collison is represented by red 
symbols and the Aeroneb by blue symbols.  There is no significant difference between H3N2 and H1N1 with the 
Collison in either the FWB or the NHP HO chambers.  There is a significant difference between Influenza A 
subtypes with the Aeroneb in the NHP HO chamber. 
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The SF results for the influenza aerosols is summarized in Table 6.  The Collison (6.56E-
06) resulted in the highest average SF for influenza in the NOT, followed by the Aeroneb 
(5.97E-06) and the BLAM (5.03E-07).  The CV of was highest for the Aeroneb (209.8%), 
followed by the Collison (108.8%) and the BLAM (53.3%) in the NOT.  The average SF for 
influenza was higher for the Aeroneb (5.30E-06) than the Collison (1.02E-06) in the FWB 
chamber.  The CV was lower for the Aeroneb (47.9%) than the Collison (54.5%) in the FWB.  In 
the NHP HO chamber, the average SF was higher in the Aeroneb (9.70E-06) than the Collison 
(1.19E-06).  The CV was 52.3% for the Aeroneb and 34.0% for the Collison in the FWB. 
Figure 7 shows the impact of choice of aerosol generator on the SF of Influenza A.  In the 
NOT, the SF of Influenza for both the BLAM and the Aeroneb are significantly different from 
the Collison based on a two-sided Mann-Whitney U test (p-value<0.0001 and p-value=0.0145, 
respectively).  The SF of Influenza for the Aeroneb is significantly different from the Collison in 
the FWB (p-value<0.0001) and NHP HO (p-value<0.0001) chambers. 
 
Table 6 Summary of SF Results for Influenza Aerosols 
NHP HO
209.8%53.3%108.8%CV
NOT FWB
4.06E-07 5.07E-06
52.3%34.0%47.9%54.5%
SD 7.14E-06 2.68E-07 1.25E-05 5.57E-07 2.54E-06
Aeroneb
Mean 6.56E-06 5.03E-07 5.97E-06 1.02E-06 5.30E-06 1.19E-06 9.70E-06
Collison BLAM Aeroneb Collison Aeroneb Collison
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Figure 7. Spray Factor of Influenza is Higher with the Collison in the NOT and Higher with the Aeroneb in 
the FWB and NHP HO Chambers 
The Collison is represented by red symbols, the BLAM by green symbols, and the Aeroneb by blue symbols.  Error 
bars represent the median and interquartile range.  In the NOT, the SF is significantly different between the Collison 
and the BLAM (p-value<0.0001) and the Collison and the Aeroneb (p-value=0.0145).  The SF was significantly 
different between the Collison and the Aeroneb in the FWB chamber (p-value<0.0001) and the NHP head-only (p-
value<0.0001). 
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Addition of fluorescein salt to influenza samples was assessed prior to aerosol 
experiments to insure fluorescein did not neutralize influenza or interfere with influenza 
infection and lysis of MDCK cells.  Tenfold serial dilutions of fluorescein salt in ddH2O were 
made from 1mg/ml to 0.0001mg/ml.  Five virus samples were set up with 3.45ml of VGM, 
500µl of influenza virus, and 50µl of fluorescein salt.  A control sample was set up with 4.5ml 
VGM and 500µl of influenza virus.  Samples were incubated on ice for one hour to simulate 
aerosol conditions.  Three tenfold serial dilutions of each concentration of fluorescein sample 
were prepared in 1X PBS to simulate loss during aerosolization, which for influenza is about a 
two log difference between the nebulizer and the AGI.  Of the five fluorescein concentrations 
only three fluorescein concentrations were able to be read at all three dilutions: 1.0mg/ml, 
0.1mg/ml, and 0.01mg/ml.  Titer of these samples was determined by plaque assays to assess 
changes in recovery of live virus.  Table 7 shows the results of the plaque assays for each 
fluorescein concentration.  All titers were within typical variation in the plaque assay method.  
The 1.0mg/ml fluorescein salt sample had the highest change in titer from the control (+0.79 
PFU/ml).  The 0.1mg/ml fluorescein salt resulted in 0.48 PFU/ml increase in titer, while the 
0.01mg/ml fluorescein salt resulted in a 0.31 PFU/ml decrease in titer.  For the fluorescein salt 
aerosols, a concentration of 0.1mg/ml of fluorescein salt was selected due to its minimal 
interference in concentration and detectability at several dilutions lower. 
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Table 7 Effect of Fluorescein Salt on Influenza A Titer 
0.1mg/ml fluorescein 3.43E05 PFU/ml
0.01mg/ml fluorescein 2.64E05 PFU/ml
Sample Influenza Titer
Control 2.95E05 PFU/ml
1.0mg/ml fluorescein 3.74E05 PFU/ml
 
 
Table 8 summarizes the SF results for fluorescein and influenza.  In the NOT, the 
Collison resulted in a -0.10 log reduction in SF, the BLAM resulted in a 0.78 log reduction in SF, 
and the Aeroneb resulted in a 0.36 log reduction in SF.  In the FWB chamber, the Collison 
resulted in a 0.72 log reduction in SF, while the Aeroneb resulted in a 0.06 log reduction in SF.  
In the NHP HO chamber, the Collison resulted in a 0.65 log reduction in SF and the Aeroneb 
resulted in a 0.12 log reduction in SF.  Figure 8 shows a graphical representation for SF results 
for fluorescein salt and influenza in each exposure chamber.  There was a significant difference 
in SF between fluorescein and influenza with the BLAM in the NOT (p-value<0.0001) and the 
Collison in both the FWB chamber and NHP HO chamber (p-value<0.0001 for both). 
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Table 8 Log Reduction in SF for Influenza in Different Exposure Chambers 
-0.10
0.78
Collison
Aeroneb
Collison 5.07E-06
Aeroneb 9.97E-06 7.52E-06 0.12
FWB
NHP HO
0.36
6.35E-06 1.20E-06 0.72
6.73E-06 5.80E-06 0.06
1.13E-06 0.65
3.44E-06
Aerosol 
Generator
Median 
Fluorescein SF
Median 
Influenza SF
Log 
Reduction
Collison
4.32E-072.59E-06
2.68E-06 1.18E-06
BLAM
Aeroneb
NOT
4.34E-06
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Figure 8. Significant Decrease in Influenza Viability with the BLAM in the NOT and the Collison in the FWB 
and NHP HO Chambers 
Red symbols represent the Collison, green symbols the BLAM, and blue symbols the Aeroneb.  Error bars represent 
the median and interquartile range.  Fluorescein salt SF represents the maximum achievable SF for each aerosol 
generator, while influenza SF represents the actual SF achieved using a live virus. 
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Median aerosol efficiency is summarized in Table 9 for each aerosol generator.  In the 
NOT, aerosol efficiency is highest for the Collison (13.87%), followed by the BLAM (5.41%) 
and the Aeroneb (2.10%).  Both the BLAM and the Aeroneb are significantly different from the 
Collison (p-value=0.0004 and p-value=0.0021, respectively.  In the FWB chamber, the aerosol 
efficiency is higher for the Aeroneb (31.91%) than the Collison (6.84%).  The aerosol efficiency 
of the Aeroneb (32.27%) is higher than the Collison (5.35%) in the NHP HO chamber.  The 
aerosol efficiency of the Aeroneb is significantly different from the Collison in both the FWB (p-
value<0.0001) and NHP HO chambers (p-value<0.0001). 
 
Table 9 Aerosol Efficiency of Influenza in Different Exposure Chambers 
Aeroneb 32.27% <0.0001
*Based on a two-sided Mann-Whitney U test
**Signficant results in bold
NOT
Aeroneb 31.91% <0.0001
NHP HO
Collison 5.35%
Aeroneb 2.10% 0.0021
FWB
Collsion 6.84%
Collison 13.87%
BLAM 5.41% 0.0004
Aerosol 
Generator
Median Aerosol 
Efficiency
P-value
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 Particle size data was only collected for H3N2 with the Collison in the NOT and for 
H5N1 with the Aeroneb in the NHP HO chamber (Figure 9).  In the NOT, the average count 
median aerodynamic diameter (CMAD) was 1.41µm and the average mass median aerodynamic 
diameter (MMAD) was 4.16µm for the Collison.  In the NHP HO chamber, the Aeroneb 
produced particles with an average CMAD of 1.46µm and an average MMAD of 3.41µm.  Issues 
with the particle sizer prevented a more rigorous assessment of particle size with these studies. 
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Figure 9. The Collison Produces Smaller Aerosol Particles than the Aeroneb 
The CMAD and MMAD for influenza in the A) NOT with the Collison and B) in the NHP HO chamber with the 
Aeroneb.  For the Collison, the CMAD was 1.41µm and MMAD was 4.16µm.  In the NHP HO chamber, the 
Aeroneb produced particles with a CMAD of 1.46µm and an MMAD of 3.41µm. 
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4.1.3 Rift Valley Fever Virus  
Aerosolization of Rift Valley Fever Virus (RVFV) was assessed in the rodent whole-body 
(RWB) chamber for the Collison and the Aeroneb.  Spray factor (SF) results for RVFV are show 
in Figure 9 and summarized in Table 10.  Plaque assays from Aeroneb aerosols with RVFV were 
done by Amy Hartman and Michael Kujawa. Collison data was based on previous aerosol 
studies performed in 2010 by Doug Reed, Le’Kneitah Smith, Amy Hartman and Laura Bethel 
since current studies supplement with humidity, potentially altering the SF.  The average SF of 
RVFV for the Aeroneb (1.26E-06) was higher than the Collison (3.63E-07).  The CV was much 
higher for the Collison (150.66%) than the Aeroneb (59.87%).  The SF of RVFV in the Aeroneb 
was significantly different from the Collison based on a two-sided Mann-Whitney U test (p-
value=0.0073). 
 
Table 10 Summary of SF Results for RVFV Aerosols 
CV 150.66% 59.87%
Mean 3.63E-07 1.26E-06
SD 5.47E-07 7.56E-07
Collison Aeroneb
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Figure 10. Spray Factor of RVFV is Higher with the Aeroneb in the RWB Chamber 
The Collison is represented by red symbols and the Aeroneb is represented by blue symbols.  Error bars represent 
the median and interquartile range.  Using a two-sided Mann-Whitney U test, the difference in spray factor between 
the Collison and the Aeroneb is significant (p-value=0.0073). 
 
Table 11 summarizes the aerosol efficiency of the Collison and the Aeroneb for RFVF.  
Collison data was taken from aerosols performed in 2010; aerosols were done by Dr. Doug Reed 
and Le’Kneitah Smith while plaque assays were done by Amy Hartman and Laura Bethel.  
During this time, amount of sample nebulized was not recorded, and thus an assumed 3mls of 
volume aerosolized was used for calculation of aerosol efficiency for the Collison based on the 
average amount nebulized by the Collison for LVS and influenza in these studies.  The aerosol 
efficiency of the Aeroneb (6.38%) was higher than the Collison (1.59%).  The difference in SF is 
significant based on a two-sided Mann-Whitney U test (p-value=0.0037). 
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Table 11 Aerosol Efficiency of RVFV in the RWB Chamber 
*Based on a two-sided Mann-Whitney U test
**signficant results in bold
Median Aerosol 
Efficiency
Aerosol 
Generator P-value*
0.0037
Collison
Aeroneb
1.59%
6.38%
 
 
Particle size for RVFV aerosols was only collected for the Aeroneb due to issues with the 
particle sizer, shown in Figure 11.  In the RWB chamber, the Aeroneb produced particles with an 
average CMAD of 1.42µm and an average MMAD of 3.34µm. 
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Figure 11. CMAD and MMAD for RVFV Aerosols 
In the RWB chamber, the Aeroneb produced RVFV particles with an average CMAD of 1.42µm and an average 
MMAD of 3.34µm. 
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4.2 ENVIRONMENTAL PARAMETERS  
The AeroMP system controls the aerosol airflow parameters and records environmental data, 
such as relative humidity, temperature and sampler pressure within the exposure system.  Due to 
the differing methodologies employed by the aerosol generators to produce aerosols, 
environmental factors may vary between aerosol generators. 
4.2.1 Francisella tularensis 
Tables 12 and 13 summarize the relative humidity (RH) and temperature, respectively, achieved 
by each aerosol generator during LVS aerosols.  RH in the NOT ranged from 62.29% to 
101.66% with a median of 86.63% for the Collison.  The RH in the NOT for the BLAM ranged 
slightly lower (48.94% to 94.44%) with a median of 75.25%.  The RH for the Aeroneb ranged 
from 54.48% to 101.67% with a median of 67.20% in the NOT.  In the RWB chamber, the RH 
for the Collison ranged from 39.56% to 77.42% with a median of 55.25%.  The RH with the 
Aeroneb in the RWB chamber ranged from 46.09% to 90.47% with a median RH of 74.63%.  
The median temperature in the NOT was with the Collison (22.22°C), followed by the Aeroneb 
(21.94°C) and BLAM (21.86°C).  The median temperature was 21.79°C with the Collison and 
21.71°C with the Aeroneb in the RWB chamber. 
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Table 12 Summary of RH During LVS Aerosols 
NOT RWB
Aeroneb
Median 86.63% 75.25% 67.21% 55.25% 74.63%
46.09%
90.47%
39.56%
77.42%
Range
Collison BLAM Aeroneb Collison
62.29%
101.66%
48.94%
94.44%
54.48%
101.67%
 
 
Table 13 Summary of Temperature During LVS Aerosols 
NOT RWB
Collison BLAM Aeroneb Collison Aeroneb
21.71°C
Range
20.67°C
23.15°C
20.93°C
22.79°C
20.46°C
23.64°C
21.21°C
23.12°C
21.11°C
22.98°C
Median 22.22°C 21.86°C 21.94°C 21.79°C
 
 
Multiple linear regression analysis was performed to predict SF from RH, temperature, 
and sampler pressure.  Results of the regression summarized in Tables 14-18.  These variables 
significantly predicted SF in the NOT for the Collison (p-value=0.0302), but not for the BLAM 
(p-value= 0.1177) or the Aeroneb (p-value=0.5435).  Of the four variables tested, only the RH 
(p-value=0.006) added statistically significantly to the prediction.  In the RWB chamber, 
multiple linear regression analysis was statistically significant for the Aeroneb (p-value<0.0001) 
but not the Collison (p-value=0.3640).  All parameters contributed statistical significance to the 
prediction for the Aeroneb in the RWB chamber. 
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Table 14 Linear Regression of LVS with the Collison in the NOT 
      Source |       SS           df       MS      Number of obs   =        16
-------------+----------------------------------   F(3, 12)        =      4.19
       Model |  1.2059e-12         3  4.0197e-13   Prob > F        =    0.0302
    Residual |  1.1503e-12        12  9.5857e-14   R-squared       =    0.5118
-------------+----------------------------------   Adj R-squared   =    0.3898
       Total |  2.3562e-12        15  1.5708e-13   Root MSE        =    3.1e-07
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -1.84e-08   5.47e-09    -3.37   0.006    -3.03e-08   -6.50e-09
        Temp |  -8.00e-08   1.33e-07    -0.60   0.558    -3.70e-07    2.10e-07
   SampPress |   6.09e-08   2.83e-08     2.15   0.053    -8.93e-10    1.23e-07
       _cons |   4.47e-06   3.28e-06     1.36   0.198    -2.68e-06    .0000116  
 
 
Table 15 Linear Regression of LVS with the BLAM in the NOT 
      Source |       SS           df       MS      Number of obs   =        11
-------------+----------------------------------   F(3, 7)         =      2.81
       Model |  4.4971e-14         3  1.4990e-14   Prob > F        =    0.1177
    Residual |  3.7360e-14         7  5.3372e-15   R-squared       =    0.5462
-------------+----------------------------------   Adj R-squared   =    0.3517
       Total |  8.2331e-14        10  8.2331e-15   Root MSE        =    7.3e-08
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |   6.84e-09   4.50e-09     1.52   0.172    -3.80e-09    1.75e-08
        Temp |   7.99e-08   5.51e-08     1.45   0.190    -5.03e-08    2.10e-07
   SampPress |  -9.54e-09   1.47e-08    -0.65   0.536    -4.42e-08    2.51e-08
       _cons |  -2.20e-06   1.58e-06    -1.39   0.206    -5.93e-06    1.53e-06  
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Table 16 Linear Regression of LVS with the Aeroneb in the NOT 
      Source |       SS           df       MS      Number of obs   =         7
-------------+----------------------------------   F(3, 3)         =      0.87
       Model |  2.2019e-17         3  7.3396e-18   Prob > F        =    0.5435
    Residual |  2.5248e-17         3  8.4158e-18   R-squared       =    0.4658
-------------+----------------------------------   Adj R-squared   =   -0.0683
       Total |  4.7266e-17         6  7.8777e-18   Root MSE        =    2.9e-09
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -4.70e-10   4.55e-10    -1.03   0.377    -1.92e-09    9.78e-10
        Temp |  -4.25e-09   4.51e-09    -0.94   0.416    -1.86e-08    1.01e-08
   SampPress |   1.39e-09   1.45e-09     0.96   0.407    -3.21e-09    5.99e-09
       _cons |   1.53e-07   1.00e-07     1.53   0.224    -1.66e-07    4.72e-07  
 
 
Table 17 Linear Regression of LVS with the Collison in the RWB Chamber 
      Source |       SS           df       MS      Number of obs   =        15
-------------+----------------------------------   F(3, 11)        =      1.17
       Model |  3.0044e-17         3  1.0015e-17   Prob > F        =    0.3640
    Residual |  9.3870e-17        11  8.5337e-18   R-squared       =    0.2425
-------------+----------------------------------   Adj R-squared   =    0.0359
       Total |  1.2391e-16        14  8.8510e-18   Root MSE        =    2.9e-09
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |   3.92e-11   8.77e-11     0.45   0.664    -1.54e-10    2.32e-10
        Temp |  -4.92e-09   3.23e-09    -1.52   0.157    -1.20e-08    2.20e-09
   SampPress |  -1.30e-10   2.75e-10    -0.47   0.647    -7.36e-10    4.76e-10
       _cons |   1.06e-07   7.15e-08     1.48   0.168    -5.18e-08    2.63e-07  
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Table 18 Linear Regression of LVS with the Aeroneb in the RWB Chamber 
      Source |       SS           df       MS      Number of obs   =        15
-------------+----------------------------------   F(3, 11)        =     29.53
       Model |  6.4685e-14         3  2.1562e-14   Prob > F        =    0.0000
    Residual |  8.0311e-15        11  7.3010e-16   R-squared       =    0.8896
-------------+----------------------------------   Adj R-squared   =    0.8594
       Total |  7.2717e-14        14  5.1940e-15   Root MSE        =    2.7e-08
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |   5.92e-09   1.53e-09     3.88   0.003     2.56e-09    9.28e-09
        Temp |   1.59e-07   2.11e-08     7.51   0.000     1.12e-07    2.05e-07
   SampPress |  -2.06e-08   5.52e-09    -3.74   0.003    -3.28e-08   -8.50e-09
       _cons |  -4.00e-06   5.17e-07    -7.74   0.000    -5.14e-06   -2.86e-06  
 
4.2.2 Influenza 
The RH and temperature achieved for each aerosol generator is summarized in Table 14 and 
Table 15.  In the NOT, the RH ranged between 69.02% and 101.64% with a median of 82.55% 
for the Collison, 53.29% to 96.66% with a median of 80.46% for the BLAM, and 58.59% to 
101.66% with a median of 92.22% for the Aeroneb.  In the FWB chamber, the RH ranged from 
39.23% to 97.67% with a median of 66.25% for the Collison and 47.52% to 88.08% with a 
median of 62.11% for the Aeroneb.  The RH ranged from 73.01% to 92.51% with a median of 
80.96% for the Collison and 86.05% to 101.67% with a median of 101.63% for the Aeroneb in 
the NHP HO chamber.  The median temperature was highest for the Aeroneb (22.01°C), 
followed by the Collison (21.83°C) and the BLAM (21.50°C) in the NOT.  In the FWB, the 
median temperature was 22.26°C for the Collison and 22.44°C for the Aeroneb.  The median 
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temperature for the Collison was 21.51°C for the Collison and 21.35°C for the Aeroneb in the 
NHP HO chamber. 
Table 19 Summary of RH During Influenza Aerosols 
NOT FWB NHP HO
69.02%
101.64%
53.29%
96.66%
58.59%
101.66%
39.23%
97.67%
Collison BLAM Aeroneb Collison Aeroneb Collison
47.52%
88.08%
73.01%
92.51%
86.05%
101.67%
Aeroneb
Range
Median 82.54% 80.46% 92.21% 66.25% 62.11% 80.95% 101.62%
 
 
Table 20 Summary of Temperature During Influenza Aerosols 
20.55°C
23.26°C
Aeroneb
20.62°C
22.49°C
19.57°C
23.77°C
Median 21.83°C 21.50°C 22.01°C 22.26°C 22.44°C 21.51°C 21.35°C
Range
20.76°C
23.41°C
20.71°C
23.40°C
20.92°C
23.56°C
20.80°C
26.81°C
BLAM Aeroneb Collison Aeroneb Collison
NOT FWB NHP HO
Collison
 
 
Multiple linear regression to predict SF from RH, temperature, and sampler pressure was 
statistically significant for the BLAM (p-value<0.0001) in the NOT, the Aeroneb (p-
value=0.0045) in the FWB chamber, and the Collison (p-value=0.0054) in the NHP HO 
chamber.  For the BLAM in the NOT temperature (p-value=0.011) and sampler pressure (p-
value=0.049) contributed significantly to prediction, while only sampler pressure contributed 
significantly to the prediction for the Aeroneb in the FWB chamber (p-value=0.004).  Only RH 
contributed statistically significantly to the prediction for the Collison in the NHP HO chamber 
(p-value=0.001). 
 61 
Table 21 Linear Regression of Influenza with the Collison in the NOT 
      Source |       SS           df       MS      Number of obs   =        14
-------------+----------------------------------   F(3, 10)        =      2.10
       Model |  3.1748e-09         3  1.0583e-09   Prob > F        =    0.1636
    Residual |  5.0348e-09        10  5.0348e-10   R-squared       =    0.3867
-------------+----------------------------------   Adj R-squared   =    0.2027
       Total |  8.2096e-09        13  6.3151e-10   Root MSE        =    2.2e-05
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |   2.92e-07   7.71e-07     0.38   0.713    -1.43e-06    2.01e-06
        Temp |   5.52e-06   9.77e-06     0.56   0.585    -.0000163    .0000273
   SampPress |  -6.99e-06   5.28e-06    -1.32   0.215    -.0000188    4.77e-06
       _cons |  -.0001905   .0002572    -0.74   0.476    -.0007635    .0003825  
 
 
Table 22 Linear Regression of Influenza with the BLAM in the NOT 
      Source |       SS           df       MS      Number of obs   =        19
-------------+----------------------------------   F(3, 15)        =     19.86
       Model |  6.8215e-12         3  2.2738e-12   Prob > F        =    0.0000
    Residual |  1.7174e-12        15  1.1449e-13   R-squared       =    0.7989
-------------+----------------------------------   Adj R-squared   =    0.7587
       Total |  8.5388e-12        18  4.7438e-13   Root MSE        =    3.4e-07
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -1.45e-08   9.32e-09    -1.55   0.141    -3.44e-08    5.38e-09
        Temp |  -4.70e-07   1.62e-07    -2.91   0.011    -8.14e-07   -1.26e-07
   SampPress |  -9.35e-08   3.87e-08    -2.42   0.029    -1.76e-07   -1.10e-08
       _cons |   .0000114   4.34e-06     2.62   0.019     2.13e-06    .0000206  
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Table 23 Linear Regression of Influenza with the Aeroneb in the NOT 
      Source |       SS           df       MS      Number of obs   =        23
-------------+----------------------------------   F(3, 19)        =      2.35
       Model |  4.8863e-10         3  1.6288e-10   Prob > F        =    0.1052
    Residual |  1.3193e-09        19  6.9439e-11   R-squared       =    0.2703
-------------+----------------------------------   Adj R-squared   =    0.1550
       Total |  1.8080e-09        22  8.2180e-11   Root MSE        =    8.3e-06
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -3.94e-07   1.50e-07    -2.63   0.016    -7.07e-07   -8.10e-08
        Temp |  -1.95e-06   2.59e-06    -0.75   0.461    -7.37e-06    3.47e-06
   SampPress |   5.47e-07   4.84e-07     1.13   0.273    -4.66e-07    1.56e-06
       _cons |   .0000865   .0000652     1.33   0.200    -.0000499    .0002229  
 
 
Table 24 Linear Regression of Influenza with the Collison in the FWB Chamber 
Source |       SS           df       MS      Number of obs   =        15
-------------+----------------------------------   F(3, 11)        =      2.29
       Model |  1.6686e-12         3  5.5619e-13   Prob > F        =    0.1350
    Residual |  2.6718e-12        11  2.4289e-13   R-squared       =    0.3844
-------------+----------------------------------   Adj R-squared   =    0.2165
       Total |  4.3403e-12        14  3.1002e-13   Root MSE        =    4.9e-07
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -1.55e-08   9.61e-09    -1.61   0.135    -3.67e-08    5.65e-09
        Temp |   8.41e-08   1.15e-07     0.73   0.480    -1.69e-07    3.37e-07
   SampPress |  -9.09e-08   2.14e-07    -0.42   0.679    -5.62e-07    3.80e-07
       _cons |  -5.98e-07   2.32e-06    -0.26   0.802    -5.72e-06    4.52e-06  
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Table 25 Linear Regression of Influenza with the Aeroneb in the FWB Chamber 
Source |       SS           df       MS      Number of obs   =        18
-------------+----------------------------------   F(3, 14)        =      6.87
       Model |  9.0013e-11         3  3.0004e-11   Prob > F        =    0.0045
    Residual |  6.1146e-11        14  4.3675e-12   R-squared       =    0.5955
-------------+----------------------------------   Adj R-squared   =    0.5088
       Total |  1.5116e-10        17  8.8917e-12   Root MSE        =    2.1e-06
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -4.89e-08   1.19e-07    -0.41   0.688    -3.04e-07    2.07e-07
        Temp |   1.40e-06   1.68e-06     0.83   0.420    -2.21e-06    5.01e-06
   SampPress |  -8.94e-07   2.61e-07    -3.43   0.004    -1.45e-06   -3.35e-07
       _cons |  -.0000291   .0000445    -0.65   0.524    -.0001245    .0000663  
 
 
Table 26 Linear Regression of Influenza with the Collison in the NHP HO Chamber 
      Source |       SS           df       MS      Number of obs   =        12
-------------+----------------------------------   F(3, 8)         =      9.33
       Model |  1.5028e-12         3  5.0094e-13   Prob > F        =    0.0054
    Residual |  4.2944e-13         8  5.3680e-14   R-squared       =    0.7778
-------------+----------------------------------   Adj R-squared   =    0.6944
       Total |  1.9322e-12        11  1.7566e-13   Root MSE        =    2.3e-07
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -6.73e-08   1.36e-08    -4.96   0.001    -9.85e-08   -3.60e-08
        Temp |  -6.92e-08   1.71e-07    -0.41   0.696    -4.63e-07    3.24e-07
   SampPress |   7.14e-08   6.00e-08     1.19   0.269    -6.70e-08    2.10e-07
       _cons |   8.55e-06   4.27e-06     2.00   0.080    -1.29e-06    .0000184  
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Table 27 Linear Regression of Influenza with the Aeroneb in the NHP HO Chamber 
      Source |       SS           df       MS      Number of obs   =        23
-------------+----------------------------------   F(3, 19)        =      1.48
       Model |  7.1099e-11         3  2.3700e-11   Prob > F        =    0.2516
    Residual |  3.0412e-10        19  1.6007e-11   R-squared       =    0.1895
-------------+----------------------------------   Adj R-squared   =    0.0615
       Total |  3.7522e-10        22  1.7056e-11   Root MSE        =    4.0e-06
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -3.73e-07   1.93e-07    -1.94   0.068    -7.76e-07    3.03e-08
        Temp |  -7.72e-07   7.35e-07    -1.05   0.307    -2.31e-06    7.66e-07
   SampPress |  -4.11e-07   8.51e-07    -0.48   0.634    -2.19e-06    1.37e-06
       _cons |   .0000588   .0000305     1.93   0.069    -4.99e-06    .0001225  
4.2.3 Rift Valley Fever Virus 
Table 16 and Table 17 summarize the RH and temperature achieved by each aerosol generator 
during Rift Valley Fever Virus (RVFV) aerosols in the Rodent whole-body chamber (RWB).  
The median RH achieved by the Collison was 38.41% with a range of 25.68% to 46.03%.  The 
RH with the Aeroneb ranged from 79.86% to 89.14% with a median RH of 83.40%.  The median 
temperature was 23.36°C with the Collison and 22.77°C with the Aeroneb. 
 
Table 28 Summary of RH During RVFV Aerosols 
Median 38.41% 83.40%
Collison Aeroneb
Range
25.68%
46.03%
79.86%
89.14%
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Table 29 Summary of Temperature During RVFV Aerosols 
20.64°C
25.69°C
22.27°C
23.81°C
Median 23.36°C 22.77°C
Collison Aeroneb
Range
 
 
 Multiple linear regression analysis to predict SF from RH, temperature, sampler pressure, 
and outside relative humidity was not statistically significant for either the Collison or the 
Aeroneb in the RWB chamber. 
 
Table 30 Linear Regression of RVFV with the Collison in the RWB Chamber 
      Source |       SS           df       MS      Number of obs   =        20
-------------+----------------------------------   F(2, 17)        =      1.03
       Model |  5.9585e-13         2  2.9792e-13   Prob > F        =    0.3778
    Residual |  4.9108e-12        17  2.8887e-13   R-squared       =    0.1082
-------------+----------------------------------   Adj R-squared   =    0.0033
       Total |  5.5066e-12        19  2.8982e-13   Root MSE        =    5.4e-07
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |   1.12e-08   3.90e-08     0.29   0.777    -7.10e-08    9.34e-08
        Temp |   3.95e-07   4.07e-07     0.97   0.346    -4.64e-07    1.25e-06
       _cons |  -9.16e-06   .0000106    -0.86   0.402    -.0000316    .0000133
       _cons |   .0000588   .0000305     1.93   0.069    -4.99e-06    .0001225  
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Table 31 Linear Regression of RVFV with the Aeroneb in the RWB Chamber 
      Source |       SS           df       MS      Number of obs   =         7
-------------+----------------------------------   F(3, 3)         =      6.99
       Model |  2.9959e-12         3  9.9863e-13   Prob > F        =    0.0722
    Residual |  4.2841e-13         3  1.4280e-13   R-squared       =    0.8749
-------------+----------------------------------   Adj R-squared   =    0.7498
       Total |  3.4243e-12         6  5.7072e-13   Root MSE        =    3.8e-07
------------------------------------------------------------------------------
          SF |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
          RH |  -2.22e-07   1.21e-07    -1.84   0.163    -6.06e-07    1.62e-07
        Temp |  -3.01e-07   6.16e-07    -0.49   0.659    -2.26e-06    1.66e-06
   SampPress |   3.71e-09   1.99e-07     0.02   0.986    -6.28e-07    6.36e-07
       _cons |    .000027   6.62e-06     4.08   0.027     5.95e-06    .0000481  
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5.0  DISCUSSION 
Aerobiology is the study of airborne biological particulates, such as bacteria, viruses, or pollen, 
and the factors that affect the dispersion of these airborne particles.  Aerosol research is 
necessary for studying infections spread through the respiratory route and developing 
therapeutics and vaccines.  Prior to beginning studies with animal models it is important to 
characterize and understand the effect different aerosol techniques, equipment, and 
environmental parameters can have on the reliability and reproducibility of a research design. 
Aerosol performance can be affected by a variety of different factors.  Pre-aerosolization 
factors occur prior to the aerosol experiment and include pathogen growth conditions or 
equipment selection [53].  Faith et al. showed aerosol performance of LVS improved when the 
bacterium was grown in BHI broth rather than Mueller Hinton Broth; [24]. other studies suggest 
bacteria are more resistant to the effects of aerosolization in the resting or lag phase of growth 
[53].  Aerosolization factors are factors that occur during the actual aerosol experiment, and can 
include relative humidity, temperature, or air leaks.  Post-aerosolization factors describe events 
that occur after the aerosol and are usually dependent on host factors of the animal model, such 
as susceptibility [53]. 
This study only examined a few factors that can potentially affect aerosol performance, 
but attempts were made to control potential confounding factors.  The same method was used to 
culture bacteria and the same stock of virus was used for aerosols.  While RH and temperature 
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were not controlled and others were hard to predict (such as air leaks), the parameters of the 
aerosol system were kept constant for each pathogen.  Animals were not used in these studies to 
avoid the potential for bias based on disease outcome of the animal models.   
Aerosol performance of the BLAM and the Aeroneb was statistically different from the 
Collison for LVS, influenza, and RVFV in all exposure chambers tested.  In the NOT, the 
Collison achieved a higher SF and aerosol efficiency than both the BLAM and the Aeroneb.  
However, in the RWB, FWB, and NHP HO chambers, the Aeroneb achieved a higher SF and 
aerosol efficiency than the Collison for LVS, influenza, and RVFV.  While the Aeroneb showed 
data suggesting better aerosol performance with certain exposure chambers, the BLAM did not 
exceed the aerosol performance of the Collison for any of the organisms. 
Interestingly, influenza spray factor was not significantly different between H1N1 and 
H3N2 with the Collison in the FWB or the NHP HO chamber, but H3N2 had a significantly 
different spray factor from H1N1 and H5N1 in the NHP HO chamber with the Aeroneb.  The 
data with the Aeroneb correlates with previous studies indicating H3N2 has an improved 
transmissibility compared to H1N1[54].  However, it is unclear why this trend is not seen 
between the two strains with the Collison.  This data suggests that H1N1 can be used as a 
surrogate for H5N1 when testing and selecting aerosol equipment for aerosol experiments. 
It is important to note the Collison and the BLAM used 10mls of sample for aerosol 
generation while the Aeroneb only used 5mls.  In a ten-minute aerosol, the Collison aerosolized 
an average of 3mls of sample, the BLAM approximately 1ml of sample, and the Aeroneb an 
average of 4mls of sample.  While the SF allows for determination of starting concentration 
needed to reach a target dose, the SF does not account for potential increases in aerosol 
performance due to volume of sample aerosolized.  Aerosol performance was also assessed by 
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aerosol efficiency, which is the ratio of the actual aerosol concentration to the theoretical aerosol 
concentration as determined by the volume and concentration aerosolized.  For each aerosol 
generator, aerosol efficiency correlated with the SF results.  This indicates that the improvement 
in SF for the Aeroneb compared to the Collison in the whole-body and head-only chambers are 
not due to rate at which liquid is aerosolized. 
Prior studies suggest the Collison may cause damage to pathogens during aerosolization 
due to the recirculation of sample.  Fluorescein salt was added to some experiments to act as a 
surrogate for the microorganisms to determine the ideal SF of each aerosol generator.  The small 
size and lack of a membrane ensure the fluorescein salt will not be damaged during 
aerosolization, and thus any loss of sample can be attributed to leaks in the exposure system or 
adhesion of aerosol particles to equipment, such as the walls of the exposure chamber.  Aerosol 
performance for pathogens can be affected by the natural loss due to the exposure system and 
loss of viability of the organism during aerosolization.  A lower SF for the pathogen relative to 
that for fluorescein salt is assumed to be due to loss of viability of the pathogen.  Loss of 
organism viability correlated with SF and aerosol efficiency results.  In the NOT, there was less 
reduction in SF for LVS and influenza relative to fluorescein with the Collison, while in the 
whole-body and head-only chambers there was less of a reduction in SF relative to fluorescein 
with the Aeroneb for LVS, influenza, and RVFV. 
Despite the modified configuration of the BLAM and the use of single pass atomization, 
the Collison still had better aerosol performance as measured by the SF, aerosol efficiency, and 
loss of viability.  Interestingly, the Aeroneb had better aerosol performance than the Collison for 
all organisms in the whole-body and head-only chambers, but not in the NOT.  A potential 
reason for this discrepancy in performance could be due to the length of the mixing tube.  The 
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whole-body and head-only chambers have a longer mixing tube than the NOT.  Thus, in the 
NOT aerosol particles do not have as much time to desiccate. Particles may remain larger which 
could improve survival.  The AeroMP was programmed to use 0.5 L/min of dilution air with the 
Collison while the BLAM needed no dilution air.  The shorted mixing tube of the NOT can result 
in larger aerosol particles that can condense out of the aerosol.  The dilution air aids in 
desiccation of aerosol particles.  The lack of dilution air used with the BLAM could explain the 
poor aerosol performance of the BLAM compared to the Collison.  The poor performance of the 
Aeroneb with the NOT was surprising.  Unlike the Collison and BLAM which used the short 
mixing tube of the NOT to dry out aerosol particles, the Aeroneb used tubing to connect to the 
mixing tube of the NOT.  For the Aeroneb, the length of tubing from the generator to the NOT 
may affect desiccation of aerosol particles, with longer tubing resulting in too much desiccation, 
and shorter tubing resulting in inadequate desiccation. In agreement with this, the reduction in SF 
for LVS with the Aeroneb in the NOT relative to fluorescein was the highest of any of the 
nebulizer/chamber/pathogen combinations tested. Length of tubing from the aerosol generator to 
the NOT was not examined in this study and thus is a potential factor to examine to determine if 
there is an effect on aerosol performance in the NOT.  
To evaluate whether other aspects of the aerosol setup impact aerosol performance, a 
multiple linear regression was performed for each aerosol set up to determine if RH, temperature, 
and sampler pressure affect SF.  RH contributed significantly to the prediction in both the NOT 
and the RWB chamber, but RH had an inverse relationship with the SF in the NOT, meaning the 
SF increases as RH decreases in this exposure chamber.  This could be due to the shorter mixing 
tube.  A higher humidity could reduce desiccation, potentially causing aerosol particles to 
condense out of the aerosol.  RH and temperature were positive predictors for the SF of LVS 
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with the Aeroneb in the RWB chamber.  This data correlates with previous studies indicating 
humidity lower the 55% reduces the SF [24].  While the relationship was not seen with the 
Collison in the RWB chamber, the median RH of the Collison suggests the RH was often low 
enough to reduce aerosol performance. 
The multiple regression significantly predicted the SF of influenza with the BLAM in the 
NOT, the Aeroneb in the FWB chamber, and the Collison in the NHP HO chamber.  For the 
BLAM in the NOT, temperature and sampler pressure contributed significantly to the prediction 
model.  For the Aeroneb in the FWB chamber, sampler pressure is statistically significant to the 
model.  In the NHP HO chamber with the Collison, RH contributed significantly to the model.  
While the model is not significant for the other setups, RH is significantly correlated with SF for 
the Aeroneb in the NOT and results are suggestive that RH is correlated with the Aeroneb in the 
NHP HO chamber.  In all cases, the RH was a negative predictor for the SF, indicating improved 
aerosol performance of influenza may be correlated with lower humidity.  This is intriguing 
because epidemiological studies and transmission studies in animal models have suggested that 
influenza transmissibility is higher at lower humidity. Why lower humidity would correspond 
with increased transmission is not clear. 
In the RWB chamber with the Aeroneb, there was a positive correlation between 
temperature and LVS SF.  While the range of temperature with the Collison and Aeroneb was 
very narrow, the Aeroneb had a slightly lower median temperature.  This suggests that similar to 
RH, there is a point at which temperature affects aerosol performance of LVS.  In the NOT with 
the BLAM, temperature was a negative predictor for the SF of influenza.  Thus, this data 
suggests influenza has improved survival in lower temperatures.  However, due to the lack of 
correlation between temperature and SF with the other aerosol generators and the small range of 
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temperature achieved during the aerosols these findings could be a spurious correlation.  Sample 
pressure was an inverse predictor for the BLAM and the Aeroneb.  In the aerosol exposure 
system, the sampler pressure is typically less than -6.0in Hg.  Aerosol performance of several 
aerosols was much lower than expected, leading to an investigation of the cause.  Examination of 
the recorded aerosol parameters revealed higher sampler pressures are associated with poor 
aerosol performance.  Thus, the regression models showing an inverse relationship between SF 
and sampler pressure supports this observation.  Sampler pressure was not significant for other 
aerosol setups because all sampler pressures fell within normal range. 
The regression model to predict SF from RH, temperature, and sampler pressure was not 
significant for Rift Valley Fever Virus with the Collison or the Aeroneb.  Thus, RH and 
temperature do not play a role in the improved aerosol performance observed with the Aeroneb 
for RVFV.  Sampler pressure was within normal range for all RVFV aerosols, and thus did not 
affect aerosol performance. 
In the nose-only tower, the Collison had better aerosol performance than the Aeroneb, 
while in the whole-body and head-only chambers, the Aeroneb had better aerosol performance.  
Prior studies indicate aerosol performance of LVS is improved with higher humidity, and the 
multiple regression analysis from this study supports this data.  The Collison was able to produce 
higher humidity than the BLAM and the Aeroneb in the NOT, and the Aeroneb was able to 
achieve a humidity higher than the Collison in the RWB chamber.  This could explain why the 
Collison has better aerosol performance than both alternatives in the NOT, but the Aeroneb has 
better aerosol performance than the Collison in the RWB chamber.  For influenza and RVFV, the 
cause of improved aerosol performance seen in the whole-body and head-only chambers is 
harder to determine.  Examined environmental parameters were not the cause of improved 
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aerosol performance for these viruses.  This suggests it is the method used to produce aerosols, 
rather than the resulting RH or temperature, that improved aerosol performance for influenza and 
RVFV with the Aeroneb. 
While the SF was lower for the Aeroneb in the NOT, if high infectious doses are not 
required for experiments, the Aeroneb may be a better choice for aerosol experiments since less 
sample is needed and the coefficient of variation was lower than the Collison potentially giving 
greater reproducibility between aerosols.  These results support that there is currently no ‘one 
size fits all’ aerosol generator, and aerosol performance of different aerosol generators should be 
fully characterized for different microorganisms to allow for appropriate selection of aerosol 
equipment based on the goals of the experimental design. While the data presented here would 
not lend toward recommending the BLAM for the pathogens/chambers tested, the data would 
suggest that the Aeroneb is potentially a suitable alternative to the Collison. 
5.1 PUBLIC HEALTH SIGNIFICANCE 
5.1.1 Bioterrorism Defense 
Biological weapons are defined as any infectious agent or toxin derived from a living organism 
and are just one of the many tools terrorists can use to harm the government or the population to 
further their political or social agenda [55, 56].  These attacks can be inflicted directly on 
populations or indirectly by attacking crops or farm animals [55, 56].  Infectious diseases have 
been used throughout history as weapons, but today developing these weapons is relatively cheap 
and very effective; there are many bacteria and viruses readily accessible in the environment that 
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could be used as biological weapons.  Corpses infected with plague were catapulted over walls in 
1346 during the siege of Kaffa; smallpox infested blankets were given to Indians loyal to the 
French during the French and Indian War; anthrax was mailed to governmental officials and the 
news media in 2001 [55, 56].  Even individuals can use infectious agents to harm others, such as 
the Shigella dysenteriae incident in Dallas where laboratory workers were invited to eat 
intentionally contaminated muffins and donuts in 1996 [55].  Despite the Geneva Protocol of 
1925, many countries had offensive biological weapons programs until the development of the 
Biological Weapons Convention in 1975, which banned the production of bioweapons [55].  
However, Iraq admitted to researching offensive use of biological weapons in 1991 and Russia in 
1992 [55].   
With the threat of biological attacks, the United States continues researching potential 
bioterrorism agents to help defend the nation against an attack through studying disease 
pathogenesis and developing vaccines and therapeutics.  Potential biological weapons will cause 
high mortality, be very contagious and virulent at low doses, have predictable incubation times, 
and be difficult to identify early due to nonspecific symptoms.  Studies indicate that aerosol will 
be the most likely method of attack since aerosol dissemination is not easily detectable, hard to 
defend against, and has the potential to reach millions in a short time span [55].  It is difficult to 
develop vaccines and therapeutics for many biological select agents and toxins due to the low 
incidence of disease, and since aerosolization is generally not the natural method of transmission 
disease pathogenesis may be different from natural routes of transmission [55].   Thus, it is 
vitally important for public health to perform aerosol studies in animals to study disease 
pathogenesis and test vaccines and therapeutics to help prevent or contain biological attacks. 
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5.1.2 Animal Models of Human Respiratory Infections 
The use of animal models dates back to ancient Greece, where animals were used to better 
understand human anatomy and physiology [57].  These initial observational animal studies 
involved outbred animals.  As the use of animal models transitioned into experimental use, the 
need to control genetic variability became apparent [57].  Individuals such as Clarence Little 
began inbreeding mice to reduce genetic variability, eventually reaching the ability to breed 
genetically identical mice [57].  Advances in the field of genetics, such as the Cre-Lox system, 
allow the manipulation of animal genomes to create specific disease models that are not naturally 
available [57]. 
The Animal Efficacy Rule allows the FDA to rely on evidence produced from animal 
studies rather than human clinical trials to determine the effectiveness of vaccines or therapeutics 
[9-11].  Data from animal studies can be used if the mechanism of toxicity is understood, if the 
desired effect is shown in animal models expected to correlate with the human response, if the 
study end point is related to the desired effect in humans, and if effective dose can be predicted 
from pharmacokinetic and pharmacodynamic data [9-11].  The implementation of the FDA 
Animal Rule increased the importance of animal models in vaccine and therapeutic development.  
Laboratory accidents in the early 20th century demonstrated that pathogens not normally spread 
through aerosols, such as alphaviruses, can cause disease through the respiratory route when 
aerosolized. Subsequently, these agents were evaluated as potential offensive biological weapons 
by the United States and former Soviet Union [6].  Therefore the disease course and virulence in 
humans for many of these pathogens after inhalation is not known, and thus developing animal 
models is vitally important for understanding disease pathogenesis and developing therapeutics 
and vaccines [6].   
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Differences in anatomy, mucocilliary clearance, or route of administration could lead to 
variances in disease pathology in animal models of respiratory illnesses [57, 58].  Differences 
inherent in the model can be controlled by careful selection of animals that exhibit characteristics 
needed for disease progression.  Ferrets are good models for influenza because their respiratory 
tract is shaped similar to the human respiratory tract and is marked by a similar sialic acid 
receptor distribution as in humans [58].  Other confounding factors can be controlled through a 
thorough understanding of experimental design and the effects that different parameters can have 
on disease outcome.  Route of administration, particle size, and dose are all factors which can 
affect disease progression in animal models and need to be controlled [13, 21].  Thus, aerosol 
research methods and equipment need to be well characterized to optimize the development of 
animal models for diseases spread through the respiratory route [58]. 
 77 
BIBLIOGRAPHY 
 
 
1. Roy, C.J. and D.K. Milton, Airborne transmission of communicable infection-the elusive 
pathway. 2004, DTIC Document. 
2. Tellier, R., Review of aerosol transmission of influenza A virus. Emerg Infect Dis, 2006. 
12(11): p. 1657-1662. 
3. Fernstrom, A. and M. Goldblatt, Aerobiology and its role in the transmission of infectious 
diseases. Journal of pathogens, 2013. 2013. 
4. Wells, W.F., Airborne Contagion and Air Hygiene. An Ecological Study of Droplet 
Infections. Airborne Contagion and Air Hygiene. An Ecological Study of Droplet 
Infections., 1955. 
5. Mizgerd, J.P., Lung infection—a public health priority. PLoS Med, 2006. 3(2): p. e76. 
6. Roy, C., D. Reed, and J. Hutt, Aerobiology and inhalation exposure to biological select 
agents and toxins. Veterinary Pathology Online, 2010. 47(5): p. 779-789. 
7. Bosch, A.A., et al., Viral and bacterial interactions in the upper respiratory tract. PLoS 
Pathog, 2013. 9(1): p. e1003057. 
8. Roy, C.J. and M.L. M. Pitt, Infectious Disease Aerobiology: Aerosol Challenge Methods, 
in Biodefense Research Methodology and Animal Models, J.R. Swearengen, Editor. 2012, 
CRC Press. p. 65-79. 
9. Aebersold, P., FDA experience with medical countermeasures under the animal rule. 
Advances in preventive medicine, 2011. 2012. 
10. Snoy, P., Establishing Efficacy of Human Products Using Animals The US Food and 
Drug Administration’s “Animal Rule”. Veterinary Pathology Online, 2010. 47(5): p. 774-
778. 
11. Burns, D.L., Licensure of vaccines using the Animal Rule. Current opinion in virology, 
2012. 2(3): p. 353-356. 
12. Food and Drug Administration, Guidance for Industry: Product Development Under the 
Animal Rule. 2014. 
13. Bodewes, R., et al., Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs 
between intranasal and intratracheal routes of inoculation. The American journal of 
pathology, 2011. 179(1): p. 30-36. 
14. Driscoll, K.E., et al., Intratracheal instillation as an exposure technique for the 
evaluation of respiratory tract toxicity: uses and limitations. Toxicological Sciences, 
2000. 55(1): p. 24-35. 
 78 
15. Berendt, R., Relationship of method of administration to respiratory virulence of 
Klebsiella pneumoniae for mice and squirrel monkeys. Infection and immunity, 1978. 
20(2): p. 581. 
16. Lackemeyer, M.G., et al., ABSL-4 aerobiology biosafety and technology at the 
NIH/NIAID integrated research facility at Fort Detrick. Viruses, 2014. 6(1): p. 137-150. 
17. AeroMP Management Platform General Description. Biaera Technologies, LLC. 
18. Collison Nebulizer - Instructions. 2002, BGI, Inc.: Waltham, MA. 
19. May, K., The Collison nebulizer: description, performance and application. Journal of 
Aerosol Science, 1973. 4(3): p. 235-243. 
20. Collison Nebulizer.  [cited 2016 February 25]; Available from: 
http://chtechusa.com/products_tag_lg_collison-nebulizer.php. 
21. Thomas, R., et al., Influence of particle size on the pathology and efficacy of vaccination 
in a murine model of inhalational anthrax. Journal of medical microbiology, 2010. 
59(12): p. 1415-1427. 
22. Zhen, H., et al., A systematic comparison of four bioaerosol generators: Affect on 
culturability and cell membrane integrity when aerosolizing Escherichia coli bacteria. 
Journal of Aerosol Science, 2014. 70: p. 67-79. 
23. Hess, D.R., Nebulizers: principles and performance. Respiratory care, 2000. 45(6): p. 
609. 
24. Faith, S.A., et al., Growth conditions and environmental factors impact aerosolization 
but not virulence of Francisella tularensis infection in mice. Front Cell Infect Microbiol, 
2012. 2: p. 126. 
25. Thomas, R.J., et al., The cell membrane as a major site of damage during aerosolization 
of Escherichia coli. Applied and environmental microbiology, 2011. 77(3): p. 920-925. 
26. Reed, D.S., et al., Differences in aerosolization of Rift Valley fever virus resulting from 
choice of inhalation exposure chamber: implications for animal challenge studies. 
Pathogens and disease, 2014. 71(2): p. 227-233. 
27. Blaustein Atomizer (BLAM) Multi-jet Model. CH Technologies (USA). 
28. Zhang, G., A. David, and T.S. Wiedmann, Performance of the vibrating membrane 
aerosol generation device: aeroneb micropump nebulizer™. Journal of Aerosol 
Medicine, 2007. 20(4): p. 408-416. 
29. CH Technologies (USA). Nose-Only Inhalation Exposure Systems.  [cited 2016 February 
24]; Available from: http://chtechusa.com/products_inhalation-noseonly.php. 
30. Roy, C.J., et al., Impact of inhalation exposure modality and particle size on the 
respiratory deposition of ricin in BALB/c mice. Inhalation toxicology, 2003. 15(6): p. 
619-638. 
31. Gater, S.T., et al., Host stress and immune responses during aerosol challenge of Brown 
Norway rats with Yersinia pestis. Front. Cell. Inf. Microbio, 2012. 2(147): p. 10.3389. 
32. Verreault, D., S. Moineau, and C. Duchaine, Methods for sampling of airborne viruses. 
Microbiology and Molecular Biology Reviews, 2008. 72(3): p. 413-444. 
33. Saini, D., et al., Sampling port for real-time analysis of bioaerosol in whole body 
exposure system for animal aerosol model development. Journal of pharmacological and 
toxicological methods, 2011. 63(2): p. 143-149. 
34. Dabisch, P., et al., Comparison of the efficiency of sampling devices for aerosolized 
Burkholderia pseudomallei. Inhalation toxicology, 2012. 24(5): p. 247-254. 
 79 
35. Skinner, J.A., et al., Immunologic Characterization of a Rhesus Macaque H1N1 
Challenge Model for Candidate Influenza Vaccine Assessment. Clinical and Vaccine 
Immunology, 2014: p. CVI. 00547-14. 
36. Steel, J., P. Palese, and A.C. Lowen, Transmission of a 2009 pandemic influenza virus 
shows a sensitivity to temperature and humidity similar to that of an H3N2 seasonal 
strain. Journal of virology, 2011. 85(3): p. 1400-1402. 
37. Dennis, D.T., et al., Tularemia as a biological weapon: medical and public health 
management. Jama, 2001. 285(21): p. 2763-2773. 
38. Adamovicz, J.J. and D.M. Waag, Tularemia, in Biodefense Research Methodology and 
Animal Models, J.R. Swearengen, Editor. 2012, CRC Press. p. 147-177. 
39. Tularemia: Statistics. 2015 October 26, 2015 [cited 2016 February 26]; Available from: 
http://www.cdc.gov/tularemia/statistics/index.html. 
40. Notes from the Field: Increase in Human Cases of Tularemia - Colorado, Nebraska, 
South Dakota, and Wyoming, January-September 2015. Morbidity and Mortality Weekly 
Report 2013 December 4, 2015 [cited 2016 February 26]; Available from: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6447a4.htm. 
41. Burke, D.S., Immunization against tularemia: analysis of the effectiveness of live 
Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. Journal of 
Infectious Diseases, 1977. 135(1): p. 55-60. 
42. Cox, N. and K. Subbarao, Global epidemiology of influenza: past and present. Annual 
review of medicine, 2000. 51(1): p. 407-421. 
43. Clark, N.M. and J. Lynch 3rd. Influenza: epidemiology, clinical features, therapy, and 
prevention. in Seminars in respiratory and critical care medicine. 2011. 
44. Swayne, D. and D. Suarez, Highly pathogenic avian influenza. Revue Scientifique et 
Technique-office International des Epizooties, 2000. 19(2): p. 463-475. 
45. Hurt, A., et al., Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to 
the neuraminidase inhibitors and adamantanes. Antiviral research, 2007. 73(3): p. 228-
231. 
46. Yang, Y., et al., Detecting human-to-human transmission of avian influenza A (H5N1). 
Emerg Infect Dis, 2007. 13(9): p. 1348-1353. 
47. Chan, P.K., Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. 
Clinical Infectious Diseases, 2002. 34(Supplement 2): p. S58-S64. 
48. Shope, R., C. Peters, and F. Davies, The spread of Rift Valley fever and approaches to its 
control. Bulletin of the World Health Organization, 1982. 60(3): p. 299. 
49. Pepin, M., et al., Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on 
pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Veterinary 
research, 2010. 41(6): p. 61. 
50. Select Agents and Toxins List.  [cited 2016 February 25]; Available from: 
http://www.selectagents.gov/SelectAgentsandToxinsList.html. 
51. Martin, V., et al., The impact of climate change on the epidemiology and control of Rift 
Valley fever. Revue Scientifique et Technique, Office International des Epizooties, 2008. 
27(2): p. 413-426. 
52. Reed, L.J. and H. Muench, A simple method of estimating fifty per cent endpoints. 
American journal of epidemiology, 1938. 27(3): p. 493-497. 
53. Goodlow, R.J. and F.A. Leonard, Viability and infectivity of microorganisms in 
experimental airborne infection. Bacteriological reviews, 1961. 25(3): p. 182. 
 80 
54. Mubareka, S., et al., Transmission of influenza virus via aerosols and fomites in the 
guinea pig model. Journal of Infectious Diseases, 2009. 199(6): p. 858-865. 
55. Anderson, P.D. and G. Bokor, Bioterrorism: pathogens as weapons. Journal of pharmacy 
practice, 2012. 25(5): p. 521-529. 
56. Beeching, N.J., et al., Biological warfare and bioterrorism. British Medical Journal, 
2002. 324(7333): p. 336. 
57. Ericsson, A.C., M.J. Crim, and C.L. Franklin, A brief history of animal modeling. 
Missouri medicine, 2013. 110(3): p. 201. 
58. National Research Council (US) Committee on Animal Models for Testing Interventions 
Against Aerosolized Bioterrorism Agents, Overcoming Challenges to Develop 
Countermeasures Against Aerosolized Bioterrorism Agents: Appropriate Use of Animal 
Models. 2006: National Academies Press (US). 
 
